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Islets are clusters of cells in the pancreas that monitor and regulate blood glucose levels. 
In culture, single islet cells reaggregate into clusters, but the reaggregation process is random, 
resulting in large variation in the cluster numbers, sizes and cell composition. Our laboratory 
created a micromold, a specialized cell culture plate, to efficiently bioengineer small, uniformly-
sized islet clusters that we called Kanslets. Currently, very little is known about the implications 
of islet cell clusters for the treatment of diabetes. The purpose of this dissertation was to 
optimize the experimental conditions necessary for islet storage (cryopreservation), drug 
discovery screening procedures, and islet health in culture utilizing Kanslets. The conventional 
methods of cryopreservation of islets use intact native islets, and the viability and function 
achieved after thawing with these methods is poor. In this dissertation work, we cryopreserved 
islets as single cells and, after thawing, reaggregated islet cells to form cryopreserved Kanslets 
using the micromold technology. We observed that the viability of cryopreserved Kanslets was 
superior to cryopreserved intact islets and cryopreserved Kanslets had the potential to lower 
blood glucose levels of diabetic rats for 10 months. Next, the effect of creating hybrid 
islets/spheroids using mixtures of cells was tested by combining cells from different human 
donors, or by combining mesenchymal stem cells (MSCs) and islet cells. In order to minimize 
the need for assay repetition during the drug screening procedures, multi-donor Kanslets, 
consisting of islet cells from different donors, were created. We observed that the multi-donor 
Kanslets were highly viable, but showed little response to drugs such as glibenclamide (insulin 
stimulator) and somatostatin (insulin inhibitor). To improve islet health in culture, islet cells were 
integrated with bone marrow MSCs and reaggregated into spheroids; these spheroids were 
highly viable even long-term in culture, but secreted less insulin irrespective of the proportion of 
MSCs and islet cells in the spheroids, when compared to the spheroids containing only islet 




also provide valuable insight for future work in reaggregating islet cells with MSCs. The work 
provides a platform for future researchers to further explore the implications of islet cell 
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1.1. Diabetes and its effect on pancreatic islets 
Diabetes is a metabolic disease represented by increased blood glucose levels either 
due to defects in insulin production resulting from destruction of β-cells, or defects in insulin 
action from reduced responses of peripheral tissues to insulin (American Diabetes Association 
2010). There has been a 390% increase in number of people suffering from diabetes since 1980 
with numbers reaching over 400 million in 2014 and this number is expected to increase to 522 
million by 2030 (World Health Organization 2016). As of 2012, in United States alone, 29 million 
people had diabetes (Center for Disease Control and Prevention 2014). Due to the various 
associated complications, life expectancy of people with diabetes is reduced by 7 years 
(Morgan, Currie et al. 2000). 
Previous studies, including ours, have found that diabetes damages the insulin 
producing structures of the pancreas, which are called islets. Diabetes not only affects the islet 
mass, it also disrupts islet morphology as well as reduces islet function (Kiraly, Bates et al. 
2007, Rawal, Huang et al. 2013). Based on the etiopathogenesis, diabetes can be classified as 
type 1 or type 2 and both of these ultimately result in destruction or damage of β-cells. In type 1 
diabetes there occurs destruction of pancreatic β-cells due to an autoimmune disorder (Vija, 
Farge et al. 2009). People with type 1 diabetes are symptomatic when they have lost more than 
80% of β-cells and cannot regulate their blood glucose levels (Willcox and Gillespie 2016). 
Approximately 90-95% of the diagnosed cases of diabetes consists of type 2 diabetes while 
type 1 accounts for approximately 5-10% of cases (Colberg, Albright et al. 2010). Type 2 
diabetes is characterized by initial systemic insulin resistance, which occurs when there is 
inadequate insulin uptake in the muscles. β-cells try to normalize the high blood glucose levels 
by hypersecreting insulin. Eventually, the β-cells fail to cope up with the increased demand 
(McCall, Toso et al. 2010). People with type 2 diabetes are symptomatic when β-cells can no 




1.2. Islet of Langerhans 
Islet function, including insulin release, is at the heart of preventing or reversing 
diabetes. Islets are housed in the pancreas, a gland located behind the stomach that lies 
transversely across the posterior abdominal wall. In humans, it is approximately 15-20 
centimeters long and weighs about 90-100 grams. The pancreas is divided into the head, neck, 
body and tail. Within each section cells exist that are both exocrine and endocrine (Dolensek, 
Rupnik et al. 2015). The exocrine portion consists of connective tissue, blood vessels, nerves, 
acini and ductal cells and secretes pancreatic enzymes, which drain into the duodenum and 
help in digestion of proteins, carbohydrates and lipids. In contrast, 1-2% of the pancreatic mass 
consists of endocrine tissue containing islet of Langerhans that secrete hormones to help 
regulate blood glucose levels. There are approximately 1 million islets of Langerhans dispersed 
throughout the pancreas (Spencer and Peakman 2009). 
1.2.1. Architecture of pancreatic islets 
Islets of Langerhans are multicellular clusters of 
endocrine cells consisting of three major types of 
endocrine cells: β-cells that secrete insulin, α-cells that 
secrete glucagon and δ-cells that secrete somatostatin 
(Figure 1). Insulin helps to lower the blood glucose 
levels. In contrast, glucagon assists in increasing blood 
glucose levels. Somatostatin inhibits the release of 
insulin as well as glucagon. 65-80% of all endocrine 
cells are β-cells. 10-15 % of a pancreatic islet is made 
up of α-cells while δ-cells make up to 5-10% (El-
Naggar, Elayat et al. 1993). Normally in rats, mice and 
rabbits, α- and δ-cells are situated in the periphery 
  
Figure 1. Immunofluorescence 
image of a typical rat pancreatic 
islet.  
Rat pancreatic islets consist of β-
cells situated in the core (60-80%; 
green), surrounded by α-cells (15-
20%; red) and δ-cells  (less than 




while the islet center mostly consists of β-cells. In other species like horses and monkeys, β-
cells occupy the periphery and α-and δ-cells are situated in the islet core. Human islets are 
more variable in arrangement of endocrine cells showing both types of arrangements and even 
random organization of the cells (Orci and Unger 1975, Orci 1976, Orci, Baetens et al. 1976, 
Murakami, Fujita et al. 1993).  
Pancreatic islets are highly vascularized and have a rich blood supply from a dense 
capillary network which is ten times higher than that of the exocrine tissue (Vetterlein, Petho et 
al. 1987, Murakami, Miyake et al. 1997, Menger, Yamauchi et al. 2001, Zanone, Favaro et al. 
2008, Schaeffer, Hodson et al. 2011). High vascularity of pancreatic islets is essential not only 
for the delivery of oxygen and nutrients to the endocrine cells, but also to serve as a pathway for 
chemical signals to reach the islets and for dispersion of islet hormones to the general 
circulation (Jansson and Hellerstrom 1986). Because of the high vascularity, there is higher 
oxygen tension in pancreatic islets than the surrounding exocrine tissue. Unfortunately, when 
these islets are isolated, they lose their blood supply and with subsequent islet cultures oxygen 
and nutrients are supplied to the pancreatic islets solely by the process of diffusion (Buchwald 
2009). 
1.2.2. Size of pancreatic islets 
Islets must live on diffusion after removal from the body, therefore for survival, the size of 
a pancreatic islet (diffusion distance) becomes very important. Human islets can vary from 
20µm to 400µm in diameter (Huang, Novikova et al. 2011). Our laboratory was the first to look 
at the differences between large and small islets. It was found that small size (<125µm in 
diameter) rat islets were more viable than large size islets (>150µm in diameter). Dead cells in 
large size islets were either scattered throughout the islets or present in the center of an islet. 
Small size islets also had significantly higher insulin secretion than large islets, and 80% of the 




transplanted with large islets were unsuccessful in reversing diabetes (MacGregor, Williams et 
al. 2006). Based on the above mentioned paper, Lehman et al. in 2007 compared the 
differences between small size (50- and large size (150-300µm) human islets and had similar 
findings. It was found that insulin secretion (basal and stimulated) was higher with small size 
islets than the large size islets. The percentage of cell death was twofold higher during hypoxic 
culture than normoxic culture conditions in large and small size islets, and also, cell death was 
twofold higher in islets with diameter of > 100µm with respect to islets less than 50µm in 
diameter (Lehmann, Zuellig et al. 2007). Later, our laboratory found that center core cell death 
was present in all the large islets (> 150µm) within 7 days in culture with respect to the small 
size islets (< 100µm), which had 91% survival rate. In this study, core death was defined as an 
area in the center of an islet with more than 50% cells that were dead. The rate of glucose 
diffusion was approximately 1.5 times greater in the periphery of small islets with respect to the 
large islets (Williams, Huang et al. 2010). Another study in our laboratory found that small islets 
had greater cell density/area with respect to the large islets, and the insulin content of the large 
islets in the core was lower, which might possibly contribute to the fact that large islets secrete 
less insulin (Huang, Novikova et al. 2011).  
1.3. Reaggregated islets: Kanslets  
Reaggregating islet cells and limiting the size of pancreatic islet seems to be one of the 
options for reducing the diffusion barrier and improving islet health. It is known that signals to 
reaggregate the islet cells are present in the neonatal (Falt, Odselius et al. 1985), fetal, 
(Masquelier, Amory et al. 1986) and adult (Halban, Powers et al. 1987) rat islets. Different 
methods of islet reaggregation have also been studied. In one study, the rat islet cells were 
dispersed into single cells and then cultured free floating in dishes for 3-4 days. (Hopcroft, 
Mason et al. 1985). Researchers found that the cells were able to morphologically organize 




another study islets were seeded in the polyglycolic acid scaffold to allow for spontaneous 
reaggregation (Weber, Hayda et al. 2008). Most of the studies published previously reported 
that islet cells reaggregated to form clusters, but neither these studies determined the cluster 
diameter, or there was great variation in the sizes of the reaggregated clusters formed (Halban, 
Powers et al. 1987, Matta, Wobken et al. 1994). Another group, reaggregated islet cells by the 
use of hanging drop method in which cells were seeded into single drops into the cell culture 
dishes (Cavallari, Zuellig et al. 2007). Islets reaggregated by the hanging drop method were 
uniform in size but the hanging drop method requires lot of labor and is not efficient if 
reaggregated islets are needed in larger quantities.  
 
Looking at these previous observations, our lab created a micromold to bioengineer 
uniform small size islets (Ramachandran, Williams et al. 2013). The micromold consists of 
A           B 
 
Figure 2. Islet reaggregation using 
micromold. 
A) Image of micromold (left) and the islet 
cells loaded into a mold (right). Scale bar= 
500µm. B) Procedure to make Kanslets. 
Native islets were dispersed into single cells 
and loaded on micromold to allow them to 




conical shaped recesses (number of recesses depending upon the size of the micromold) each 
<200µm in size (Figure 2A).  
The uniform small size islets, called Kanslets, were engineered by dispersing fresh native 
islets into single cells, and then allowing them to reaggregate over a few days in the micromold, 
yielding small-size islets (Figure 2B). Large numbers of Kanslets of uniform size can be 
produced using this procedure, as shown in Figure 3. 
Kanslets were tested for their viability, cellular composition, glucose diffusion, static and 
dynamic insulin secretion with respect to the fresh native islets. Kanslets have been shown to: 
1. Have cellular composition similar to 
native islets  
2. Have higher viability than native 
islets 
3. Have higher glucose diffusion than 
native islets 
4. Be responsive to increasing glucose 
concentrations by secreting insulin 
5. Restore and maintain 
normoglycemia when transplanted 
into diabetic rats 
In this dissertation, we will focus on how our technology of dispersing islets into single cells 
and later reaggregating can move diabetes research using three distinct approaches. First, we 
theorized that the reaggregation process would open new doors to solve the common problem 
of storage of islet cells, by allowing for the cryopreservation of the single cells and then 
reaggregation after thawing (Chapter 2). Such an approach had not been attempted before, 
 
Figure 3. Small and uniform size Kanslets.  
Light microscopy image of small and uniform 
size Kanslets after reaggregation in 




because the tools for reaggregation were inefficient and difficult to use. Next, we hypothesized 
that improved drug screening could occur if human islet cells were used in the three 
dimensional (3D) reaggregated form from multiple human donors. This hypothesis was tested 
and the results are described in Chapter 3. Finally, we built upon previous work by other labs 
indicating that the addition of mesenchymal stem cells (MSCs) to islet cells can increase their 
viability and their function. MSCs were loaded along with islet cells into the micromold to form 
spheroids and their morphology, viability and function was tested in Chapter 4.  
1.4. Reaggregating pancreatic islet cells for optimal cryopreservation 
1.4.1. Need for optimal cryopreservation procedure for pancreatic islets 
Cryopreservation is defined as the process of freezing the cells/islets at deep subzero 
temperatures resulting in the seizure of chemical, physical and biological process (Taylor and 
Baicu 2009). Current preservation protocols of pancreatic islets are not optimal. Islets stored 
with short-term preservation techniques like tissue culture have a limited life-span and there is a 
high risk of contamination (Fraga, Sabek et al. 1998). Long-term storage can be achieved by 
cryopreservation of pancreatic islets at subzero temperatures. For more than 5 decades 
researchers have been trying to optimize the cryopreservation procedure for pancreatic islets 
(Kemp, Mullen et al. 1978, Rajotte, Ao et al. 1995), but there are no consistently successful 
cryopreservation techniques. Previous studies have reported reduced islet recovery, reduced 
viability, poor or abnormal insulin secretion after thawing and poor in vivo outcomes after 
transplantation of the cryopreserved islets (Piemonti, Bertuzzi et al. 1999, von Mach, Schlosser 
et al. 2003, Omori, Valiente et al. 2007). Hence, an improved method of long-term storage of 
islets would be advantageous both for essential, for research and islet transplantation.  
Successful cryopreservation of pancreatic islet can offer several advantages. It will allow 




(Warnock and Rajotte 1988). Cryopreservation will also provide time for viability testing and 
human leukocyte antigen (HLA) matching of the islet preparation, as well as allowing time for 
quality control assays prior to transplantation (Gray, Reece-Smith et al. 1984, Lakey, Warnock 
et al. 1996). Furthermore, cryopreservation itself reduces the expression of major 
histocompatibility complex class 1 by 40% thus providing immunological benefits to the 
cryopreserved islets (Cattral, Warnock et al. 1993). Finally, the process of cryopreservation and 
thawing may help to improve islet purity (Rajotte, Warnock et al. 1983, Evans, Rajotte et al. 
1987). 
1.4.2. Damage caused by cryopreservation 
There are four major steps in the cryopreservation process: 
1. Addition of cryoprotective agent to cells/tissues 
2. Cooling the cells/tissues  
3. Thawing the cells/tissues 
4. Removing cryoprotective agents 
During these steps, cells/tissues can undergo damage. For 70 years, cellular injury 
during the process of cryopreservation and thawing has been an important focus of study 
(Storey 1990). Major factors causing cell/tissue damage during cryopreservation are thermal 
shock, the cytotoxic effects of the cryoprotectant, osmotic stress, and formation of intracellular 
and extracellular ice. As the temperature is decreased to allow cooling, the cells/tissues 
undergo cellular lesion because of thermal shock. Thermal shock can be avoided by the 
addition of a cryoprotectant in combination with slow cooling (Bakhach 2009). Dimethyl 
sulfoxide (DMSO) is the most commonly used as a cryoprotectant. It is an intracellular 
cryoprotectant with low molecular weight, capable of penetrating the cells. Once in the cells, it 




MacFarlane et al. 1984, Yu and Quinn 1994, Fuller, Dijk et al. 2003) (Fahy, MacFarlane et al. 
1984). DMSO not only stabilizes lipid membranes but also protects cellular proteins from 
denaturation (Anchordoguy, Cecchini et al. 1991).  
Despite several advantages of using a cryoprotectant during the cryopreservation 
process, cryoprotectants have been reported to cause toxicity if used in high concentrations 
(Giugliarelli, Urbanelli et al. 2016). Cryoprotectants can cause damage to cell membranes 
(Wang, Hua et al. 2007) as well as cause oxidative stress if used in higher concentrations 
(Sanmartin-Suarez, Soto-Otero et al. 2011). Furthermore, osmotic stress during the addition 
and removal of the cryoprotectant can also damage the cell. When a cryoprotectant is added to 
the solution, the cells shrink and then return to normal cell volume when the cryoprotectant 
permeates. Conversely, when the cryoprotectant is removed, cell volume expands. Cells 
undergo volume changes due to osmotic differences during cryoprotectant addition and removal 
during the process of cryopreservation and thawing, which causes cell injury and affects islet 
physical integrity (Mazur 1984, Gao, Liu et al. 1995).  
Another important factor causing cell injury during cryopreservation and thawing is the 
formation of intracellular and extracellular ice. The temperature zone between -15 to -60°C is 
considered to cause the most lethal injuries to the tissue, and the samples have to pass through 
this zone twice: once during cryopreservation, and once gain during thawing (Mazur 1963). As 
the sample cools down, the temperature at which ice crystals are initiated is called nucleation 
temperature. Control of ice formation is a critical step during the cryopreservation process 
(Morris and Acton 2013). If no ice nucleating agents are present, ice generally starts to form at 
temperatures that are much below the freezing point of the solution. The lowest possible super 
cooling temperature in most biological systems is the point of homogeneous ice nucleation, 
around or at –40°C (Lee and Costanzo 1998). During nucleation, energy is released as the 




solution before it starts to cool down again. After the initial ice nucleation event, ice crystals 
have the capacity to grow into complex clusters forming networks that can grow exponentially 
as more and more water molecules participate in complex alignments with each other. Ice that 
forms at super cooled temperatures is spontaneous and can happen at random and at 
unpredictable temperatures. Ice nucleation affects the structural, osmotic and colligative 
integrity of cells, causing physical ruptures and mechanical injury.  
Rapid ice crystallization at super cooled temperatures can also cause damage through 
formation of intracellular ice as there is increased retention of water. If extracellular ice formation 
occurs at much lower temperatures, then the chances of intracellular ice formation also 
increases. Therefore, in order to avoid uncontrolled extracellular and intracellular ice formation, 
it is recommended to initiate ice formation at temperatures not much below the melting point. 
There are many different ways to initiate ice nucleation, like touching the sample with super 
cooled needle, touching the exteriors of the sample with chilled rod or by mechanically agitating 
the sample (Stephen Butler and Pegg 2012).  
Appropriate cooling rates are also important to minimize ice formation and cell/tissue 
damage. During the process of cryopreservation, when the temperature goes down to 
approximately -5°C, cells as well as the surrounding medium are supercool. As the temperature 
lowers more, extracellular ice starts to form. At this time, to maintain osmotic equilibrium 
between the partially frozen outside of the cell and the unfrozen inside, the water molecules 
migrate to the extracellular area. During this process of freezing, cell injury depends upon the 
rate of cooling. Cell injury during freezing has been explained by Mazur in 1972 by using a two 
factor hypothesis. According to the hypothesis, when the cooling rates are too slow, cell injury 
occurs due to various solution effects like cell dehydration, extracellular ice formation and solute 
concentration. Specifically, with excessively slow cooling, cells can undergo an excessive 




concentrations for long duration of time (Tyerman, Niemietz et al. 2002). If the cooling is too 
rapid, cell injury occurs due to intracellular ice formation (Mazur, Leibo et al. 1972). In this case, 
intracellular water is not lost fast enough to maintain equilibrium; the cells become increasingly 
super cooled, eventually attaining equilibrium by freezing intracellularly (Toner, Cravalho et al. 
1993, Muldrew and McGann 1994). Extracellular ice formation also causes mechanical stress, 
leading to cell damage. Therefore, the cooling rate should be neither too rapid to allow 
intracellular ice formation, nor should it be too slow to allow excessive dehydration.  
There are chances for cellular injury during the thawing phase as well. Warming rates 
are also considered crucial with respect to cell survival after thawing. Fast thawing is preferred 
as it can prevent the growth of small intracellular ice crystals into harmful large ice crystals (Gao 
and Critser 2000). Very small ice crystals, which are formed during the cryopreservation 
procedure, behave differently when the sample is warmed slowly or rapidly. With slow warming, 
intracellular ice crystals recrystallize and grow bigger and cause damage to the tissues whereas 
with rapid cooling rates, it is difficult for the ice crystals to recrystallize and grow as the ice 
crystals simply melt (Pegg 2007). It was shown that fetal islets thawed at a fast rate had almost 
normal insulin secretion and C-peptide content and these islets also had intact structural 
integrity with respect to the islets that were slowly thawed (El-Naggar, Al-Mashat et al. 2006). 
Other causes of damage to the islets during cryopreservation are cold hypoxia, 
reoxygenation, and upregulation of inflammatory responses (Fuller, Dijk et al. 2003). Making the 
situation even worse, pancreatic islets possess poor antioxidant defense mechanisms (Modak, 
Parab et al. 2009), hence oxidative stress during the cryopreservation process can lead to 






1.4.3. Vitrification and microencapsulation  
Vitrification and microencapsulation of the islets have been suggested to prevent injury 
caused due to the cryopreservation process. Vitrification uses compounds like sugars that 
prevent the ice formation by keeping the water in the non-crystalline state (Armitage and Rich 
1990), but the use of common vitrification compounds like poly vinyl pyrrolidone and poly 
ethylene glycol during the vitrification process can exert some toxicity. Also, vitrification requires 
the use of high concentrations of cryoprotective agents, which can be toxic to the cells (Fahy 
1986, Jackson, Ungan et al. 1997). It was seen that insulin secretion of the islets vitrified in the 
presence of such compounds decreased by 45% after thawing (Agudelo and Iwata 2008). 
Cryopreservation also causes damage to the microencapsulated islets resulting in their low 
viability (Zhou et al 1997). In particular, cryopreservation damages the structure of the agarose 
gel microcapsules, thus affecting the diffusion of molecules like glucose and insulin within the 
gel (Agudelo and Iwata 2008).  
1.4.4. Cryopreservation techniques described in the literature 
The conventional protocols described in the literature for cryopreservation of human 
islets are based on the results of the animal models and these protocols are based on the same 
principle of slow freezing and fast thawing with the use of DMSO, and sucrose dilutions. 
Researchers have stressed appropriate cooling and thawing rates to prevent intracellular ice 
formation (Taylor and Benton 1987, Miyamoto, Kenmochi et al. 1994). Most studies have shown 
that slow freezing to -40 ºC and rapid thawing from -196 ºC have provided more viability in 
rodent islets (Rich, Swift et al. 1993). As described previously, with a fast freezing rate there is 
not enough time for water to leave the cells; instead with slow freezing rates, water gets enough 
time to leave the cells, resulting in an increase in the intracellular solute concentration. 
Increased intracellular solute concentration lowers the equilibrium melting point of the solution, 




1996). Slow freezing and rapid thawing has been suggested for human islets as well. 1.5M, or 
10%, DMSO as opposed to 2M DMSO (Lakey, Anderson et al. 2001) has been suggested for 
human islets, as islet recovery was 74% approximately with 1.5M DMSO while recovery was 
only 62% in 2M DMSO. Our protocol for cryopreservation is based on slow freezing and rapid 
thawing to avoid intracellular ice formation. 
Conventional cryopreservation protocols described in the literature used intact native 
islets for cryopreservation. Native Islets are multicellular structures. Multicellular structures are 
more difficult to cryopreserve than single cells (reviewed in Chapter 2); hence, for experiments 
in Chapter 2, we cryopreserved islets as single cells, and after thawing, allowed them to 
reaggregate in the micromold to form Kanslets. We compared the outcomes of this form of 
cryopreservation to the conventional method used for cryopreservation of intact native islets.  
1.4.5. Glucose stimulated insulin secretion (GSIS)  
The primary function of pancreatic β-cells is to help monitor and regulate blood glucose 
levels. High concentration of blood glucose is the primary stimulus to β-cells to secrete insulin. 
Thus, glucose stimulated insulin secretion (GSIS) is the most common outcome to assess in 
vitro function of islets. GSIS is the increase in insulin levels with respect to the basal insulin 
secretion in response to external glucose levels. An increase in blood glucose levels causes 
increase in intracellular glucose levels as glucose diffuses into the β-cells with the help of 
glucose transporters (GLUT1 and GLUT2) (Newsholme, Gaudel et al. 2010). Subsequently, a 
series of downstream intracellular signaling events occur. During glycolysis, glucokinase 
phosphorylates glucose in β-cells forming fructose-1.6-biphosphate and two ATP molecules are 
converted to two ADP molecules. Fructose-1,6-biphosphate splits into 2 molecules, each 
containing 3 carbons with a phosphate group. Each of these molecule is converted into pyruvate 
and in the process 2 APT and one NADPH molecule are produced. In this whole process, a net 




mitochondria and gets oxidized generating another ATP (Muoio and Newgard 2008). An 
increase in the ATP/ADP ratio leads to closure of ATP sensitive potassium (K+) channels in the 
plasma membrane. This further leads to membrane depolarization and the opening of calcium 
(Ca2+) channels, leading to exocytosis of a small fraction of insulin granules that reside in 
docked positions near the membrane called the immediately releasable pool. 
In the first phase of insulin release there is a rapid release of insulin for approximately 4-
10 minutes followed by a reduction of insulin secretion and then increased insulin secretion 
follows for 30 minutes until it reaches plateau, called the second phase. Although several 
hypotheses have been proposed to explain the mechanism behind the second phase of insulin 
release, there is no conclusive agreement (Straub and Sharp 2002). The second phase of 
insulin secretion is supported by the docked readily releasable pool. The rate limiting step 
during the second phase of insulin secretion is the conversion of the readily releasable pools 
into immediately releasable pools (Straub and Sharp 2002). With the first and second phases of 
insulin secretion as the major outcome measures for in vitro assays of islet function, it is 
important to understand all steps of the process when using GSIS to screen islet cells for the 
activity of new drugs. There are various drugs like glibenclamide, nifedipine and somatostatin 
that act through K+ and Ca2+ channels to either enhance or inhibit the insulin secretion. We 
tested glibenclamide and somatostatin for drug testing experiments in Chapter 3. Glibenclamide 
is a hypoglycemic drug, and binds to the K+ channel, leading to its closure, which results in 
opening of the Ca2+ channel and insulin secretion (Proks, Reimann et al. 2002). Whereas 
somatostatin inhibits the secretion by reducing the inflow of Ca2+ through the voltage gated Ca2+ 
channels. Somatostatin also reduces insulin synthesis. Somatostatin has also been shown to 
hinder the mobilization of insulin granules (Renstrom, Ding et al. 1996, Benali, Ferjoux et al. 











Figure 4. Mechanism of insulin secretion from β-cells after glucose stimulation. 
 A) At rest, when there is low glucose concentration, K+ channel remain open, 
membrane is hyperpolarized and there is no electrical activity hence voltage gated Ca2+ 
channels remain closed and there is no insulin secretion. B) When there is higher levels 
of glucose in the blood, glucose enters the β-cells, is metabolized leading to K+ channel 
closure and membrane hyperpolarization which leads to Ca2+ influx and insulin 
secretion. Please note: other subcellular organelles such as nucleus, mitochondria, and 











































1.5. Drug testing: reaggregated 3D islets  
1.5.1. Drugs for diabetes and need to discover new drugs 
Drugs are used to help diabetics maintain blood glucose levels within the targeted range. 
Out of all the diagnosed cases of diabetes, in 2011, 50% of people were on oral medications, 
17% were on insulin, and another 13% were on oral medications along with insulin (Center for 
Disease Control and Prevention 2012). Table 1 lists the various classes of drugs approved by 
Food and Drug Administration (FDA) for type 1 and type 2 diabetes and their mechanisms of 
action along with the adverse effects associated with them. Since the first insulin injections in 
1920’s, insulin has been the mainstay for people with type 1 diabetes. People with type 1 
diabetes have to be on intensive lifelong insulin therapy and regular blood glucose level checks. 
According to the onset, peak time and duration, insulin formulations can be classified as rapid 
acting, short acting, intermediate acting or long acting. Insulin can be administered either by 
multiple chronic injections or by infusion pumps. Along with hypoglycemia, pain and redness at 
the injection site are common side effects of insulin injections. Infusion pumps can also cause 
diabetic ketoacidosis as well as subcutaneous skin infections (Chantelau, Spraul et al. 1989).  
Type 2 diabetes is typically managed with oral medications (most commonly metformin) 
along with diet and exercise. Metformin is the only biguanide available in United States. It is one 
of the cheapest medications for people with type 2 diabetes. Metformin acts mainly by reducing 
the output of glucose by the liver and also by increasing the uptake of glucose in the skeletal 
muscles (Rojas and Gomes 2013). It is commonly associated with gastrointestinal side effects 
as well as rare but serious adverse effects of lactic acidosis, which is one of the causes of high 
mortality rate in these patients. As the disease progresses, people with type 2 diabetes might 
require an additional oral or injectable medication with or without insulin, and it is estimated that 
around 70% of people suffering from type 2 diabetes will be on more than one type of oral 




as the second step when glycemic control cannot be achieved with exercise, diet and, 
metformin. Sulphonylureas have been used in the treatment of people with type 2 diabetes for 
more than 50 years. Sulphonylureas increase insulin secretion by closing potassium channel, 
leading to membrane depolarization and opening of calcium channel which leads to exocytosis 
and insulin release. Some studies reported cardiovascular adverse effects with first generation 
sulphonylureas like tolbutamide. Second generation sulphonylureas like glibenclamide and 
glimepiride are considered more potent and are still not free of adverse effects like 
hypoglycemia. 
Addition of thaizolidinediones to the drug regime is also common. Thaizolidinediones 
were introduced in late 1990s and help improve the body’s sensitivity to insulin (Consoli and 
Formoso 2013). Although it is well tolerated, it can also cause hypoglycemia and still needs to 
be used with caution in people with heart diseases. It can cause weight gain, which can 
increase the risk of mortality in this population (Maggio and Pi-Sunyer 2003). If avoiding 
hypoglycemia and weight loss is a priority, then injectable drugs like incretin mimetics and 
Dipeptidyl peptidase-4 (DPP-4) inhibitors are preferred. Incretin mimetics and DPP-4 inhibitors 
first came to market in 2005 and 2006, respectively. Incretin mimetics mimic the action of 
incretin hormone, glucagon-like peptide 1 (GLP1), which stimulates pancreas to produce more 
insulin and also slows gastric emptying and stimulates the satiety center in the central nervous 
system. DPP-4 inhibitors inhibit the action of the DPP-4 enzyme which shorten the half-life of 
GLP1 and thereby, DPP-4 inhibitors extend the action of GLP1. Incretin mimetics have been 
known to cause pancreatitis and renal dysfunction, and DPP-4 inhibitors have shown to be 
associated with neoplastic changes and increased risk of heart disease. Amylin analog is 
another injectable drug for people with type 2 diabetes, and their mode of action is very similar 
to incretin mimetics and DPP-4 inhibitor class of drugs. Alpha glycosidase inhibitors are another 




and thereby cause delay in carbohydrate digestion and reduce postprandial hyperglycemia. This 
class of drugs is preferred for patients whose blood glucose levels rise after a meal containing 
complex carbohydrates. Gastrointestinal discomfort like flatulence, abdominal discomfort, and 
diarrhea caused by fermentation of carbohydrates by flora in the large intestine is one of the 
common side effects of alpha glycosidase inhibitors. 
Despite availability of a number of drugs, it has been difficult to achieve tight glycemic 
control in people with diabetes. Studies suggest that approximately 60% of the people with type 
2 diabetes have hemoglobin A1c levels still above 7 (Koro, Bowlin et al. 2004, Saydah, Fradkin 
et al. 2004). Moreover, even with intensive treatment people with diabetes still develop 
complications, which worsen over time (Ichii and Ricordi 2009).There is a need to discover new 
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1.5.2. Drug screening/ discovery process 
New drug discovery is time consuming and requires around a billion dollars in 
investment (Dickson and Gagnon 2004). The steps involved in the drug screening discovery 
process are the drug discovery phase, preclinical phase, clinical trials and finally FDA approval. 
Figure 5 describes the time involved during each step of the drug screening and discovery 
process. The first step is the drug discovery phase, which involves target identification and 
validation, assay development, lead identification and lead optimization. Understanding the 
molecular mechanism of the disease is important even before the drug enters the drug 
discovery pipeline, this is carried out during the pre-discovery phase (Pharmaceutical Reserach 
and Manufacturers of America 2016). Intensive research is carried out to identify the drug-like 
molecules before the drug enters the preclinical phase. This initial basic step helps to develop a 
hypothesis that stimulation or inhibition of an identified target like a certain protein or a 
ribonucleic acid (RNA) will result in the desired effect in the diseased state. Target identification 
and validation is one of most important steps during the drug screening discovery process. 
Target validation can be performed in in vitro or in vivo models.  
Once the target has been identified and validated, compound screening is performed to 
identify the molecule, called the hit molecule, which has desired activity on the target during the 
screening process. Various screening methods like high-throughput screening, focused 
screening or physiological screening can be performed to identify the molecules that are best to 
work with (Fox, Farr-Jones et al. 2006, Boppana, Dubey et al. 2009). Dose response curves are 
generated for each hit molecule in primary and then more complex secondary assays. When a 
drug is about to enter the lead phase, the primary focus is to identify if there are any structure-
activity relationships, identify the magnitude of activity and selectivity of each compound, and 
also to collect data about how the compound is absorbed, distributed, metabolized, and 




the lead optimization phase, deficiencies in the structure of the drug like molecule are improved 
and also metabolic profiling studies are carried out before the drug candidate makes it to the 
preclinical phase (Hughes, Rees et al. 2011). 
 
Source: yalescientific.org 
To begin with, thousands of compounds may be screened, but on average only 100’s of 
compounds will make it to the preclinical phase and a very few of them enter the clinical phase. 
One out of 5 compounds in the clinical phase will get FDA approval and make it to the market 
(McKim 2010). Sometimes the failure even occurs during the phase 3 clinical trials. One of the 
biggest challenges faced by pharmaceutical industry is the failure of a drug candidate in the 
 
 
Figure 5. Steps and the time involved in the drug discovery process.  
It takes approximately 12-15 years to go from 10,000 compounds tested during the drug 




preclinical and clinical trials. If failure occurs at the later stages, which leads to major time 
setbacks and tremendous financial loss. Therefore, it is crucial to identify the failures as early in 
the pre-discovery phase as possible to save time and avoid financial loss as well as to make the 
drug screening procedure more efficient. Molecules that do not behave when screened as they 
would in the human body are at the heart of failed drug screening procedures. An article by 
William Bians suggests that avoiding repetitions at various stages of drug development can 
substantially help bring down the cost and time involved with the drug testing procedure (William 
Bians 2004). Hence in Chapter 3, we created 3D Kanslets, consisting of human islet cells from 
various donors using our micromold and we hypothesized that multi-donor Kanslets would give 
an averaged dose response of individual donors in the study. If the hypotheses were correct, 
then the number of repetitions in the early drug screening process could be reduced. 
1.5.3. Two-dimensional (2D) and three-dimensional (3D) drug testing 
In addition to decreasing the number of repetitions by pooling cells from multiple donors, 
screening drugs in a more natural condition, comparable to the human body, would also 
theoretically reduce the errors in drug screening. 2D monolayer culturing of cells has been used 
for drug testing and discovery for decades. 3D cell cultures more closely resemble the 
architectural microenvironment of natural tissue with respect to the standard 2D cultures (Graf 
and Boppart 2010). In 3D cell aggregates/spheroids, cell–cell interactions and cell–extracellular 
matrix interactions more closely mimic the natural environment found in vivo, so that the cell 
morphology resembles its natural shape in the body. Not only the spatial organization of the cell 
surface receptors engaged in interactions with surrounding cells is different in 3D structures 
than in 2D, but a 3D structure also induces physical changes to cells. These spatial and 
physical aspects in 3D cultures affect the signal transduction and ultimately influence gene 




3D tissue culture has recently been extensively studied in the oncology field with the 
conclusion that 3D culturing of multicellular spheroids mimic the in vivo environment more than 
2D culturing (Debnath and Brugge 2005, Meng 2010, LaBarbera, Reid et al. 2012, Alexander, 
Price et al. 2013). Different techniques for 3D culturing have been developed and multicellular 
tumor spheroids have been studied as an in vitro 3D model over the past decades to study 
tumor cell proliferation, apoptosis, differentiation, gene expression, and metabolism (Mueller-
Klieser 1987). Tumor spheroids resemble the morphological as well as the physiological 
characteristics of the in vivo tumor and hence are considered an improved in vitro model. For 
example, cells grown in monolayer usually do not contain necrotic/dead cells, as the dead cells 
get detached from the monolayer. Also, cells in 2D culture are more flat and stretched out than 
those found in vivo. Further, 3D spheroids have a higher degree of morphological and functional 
differentiation than cells grown in monolayer culture (Sutherland, Sordat et al. 1986, Streuli, 
Bailey et al. 1991, Mayer, Klement et al. 2001), which can be important in testing drugs 
targeting mature cells. In 3D cultures, cells are often more resistant to treatment compared to 
those in 2D culture system, often being better predictors of in vivo drug responses. Due to this 
lack of resistance in the 2D models, drugs may appear to be effective, but when they get to in 
vivo studies they will lack efficacy. 3D spheroids have been shown to have similar growth 
kinetics, metabolic rates, and resistance to radiotherapy and chemotherapy as tumor cells in 
vivo (Sutherland and Durand 1976, Landry, Freyer et al. 1982, Nederman 1984). A study, 
looking at the difference in response of chemotherapeutic agents between leukemic cell lines in 
a 3D model in comparison to the 2D model found that the 3D model was more resistant to the 
drug induced apoptosis with respect to the 2D model and thus better predicted what happens in 
patients (Aljitawi, Li et al. 2014).   
In regards to pancreatic islets, the cellular interaction between β-cells is considered 




glucose-stimulated insulin secretion, but upon reaggregation these cells show normal secretory 
responses as seen in intact islets (Halban, Wollheim et al. 1982, Hauge-Evans, Squires et al. 
1999) (Brereton, Carvell et al. 2006). This is not surprising, as it has been shown that in 2D 
culturing there is a lack of cell-cell interaction, which is important for normal cellular function 
(Weaver, Petersen et al. 1997, Bissell, Rizki et al. 2003). Several cellular mechanisms may 
explain this difference. Connexins and cadherins, involved in cell adhesion, affect insulin 
release. Specifically, gap junctions connect β cells and these gap junctions consist of 
connexins, which form intracellular channels. These intracellular channels are required for the 
exchange of cytoplasmic ions and metabolites, allowing for the coordinated response of islet 
cells. Thus, connexins are required for fine-tuning biosynthesis, storage and release of insulin 
(Nlend, Michon et al. 2006, Bavamian, Klee et al. 2007). In addition to the gap junctions, there 
are other mechanisms requiring cell-to-cell contact that help in the regulation of insulin release 
from the β cells. The neuronal cell-adhesion molecule present between the β-cells regulates the 
cortical F-actin network. In response to glucose, the F-actin depolymerizes and actin network 
becomes disrupted, which in turn leads to insulin secretion. Bi-directional signaling between β-
cells is considered important in the regulation of insulin secretion as it also helps in 
depolymerization of F-actin network, which affects insulin secretion (Howell and Tyhurst 1982, 
Thurmond, Gonelle-Gispert et al. 2003). Thus, there are several possible molecular 
explanations for the improved response to drugs seen in 3D cell cultures compared to in 2D 
cultures. 
1.5.4. Primary cells or cell culture lines for drug testing 
The source of the cells is also important in drug screening. Either the primary cells (cells 
that are derived directly from the human donors) or the cell culture lines (cells originally derived 
from the donor tissue that can divide and grow, for a number of replications) can be utilized for 




results obtained are consistent and can be reproduced, but there are disadvantages of cell 
culture lines too. Due to the long-term culture, the phenotypic characteristics of the cells can 
change (Borrell 2010, Lee, Nam et al. 2010, Philippeos, Hughes et al. 2012) and some cell lines 
have shown to have reduced insulin secretion with time in culture (Ulrich, Schmied et al. 2002). 
Several β-cell lines have been developed and none of these cell lines are truly representative of 
primary β-cells, as they cannot accurately imitate primary β-cell function and physiology, and 
most of these cell lines have inappropriate glucose sensitivity (Efrat and Hanahan 1987, 
Gilligan, Jewett et al. 1989, Wang, Beattie et al. 1997, Baroni, Cavallo et al. 1999), hence it is 
difficult to obtain the accurate drug test results using the cell current lines.  
1.5.5. Kanslets for drug testing 
If one is to use 3D cell clusters of primary cells for drug testing, there are several 
challenges that must be overcome. In regards to pancreatic islets, there is a lot of variability in 
the insulin response of islets from different donors. It has been seen that age (Maedler, 
Schumann et al. 2006, Ihm, Moon et al. 2007) and race affect the insulin response of the islets. 
Out of the 20 times we have conducted GSIS for different experiments in our lab, we have 
measured wide variations in the GSIS curves from different donors. In addition, there is great 
variability within the same donor between different sizes of islets. When screening for drugs, the 
size of the islets that are placed in each well can alter the effects.  For example, if drug A is 
placed in a well with 5 islets that are each 400m in diameter, and drug B is placed in the 
neighboring well with 5 islets that are 50m in diameter, drug A may have a larger effect, but in 
reality it may be less potent. 
Our 3D clusters, Kanslets, created by dispersing the native islets into single cells and 
allowing them to reaggregate in the micromold for several days, are small and uniform in size. 
This uniformity along can eliminate some of the variability between the large and the small 




drugs like the calcium channel agonist, Bay K 8644; glibenclamide; tolbutamide; caffeine; 
carbachol; glucagon-like peptide-1; somatostatin; diazoxide; and sodium azide were tested on 
Kanslets. It was found that Bay K 8644, stimulated insulin secretion in native to rat islets and 
human Kanslets, but not in native human islets. The sulfonylureas (glibenclamide and 
tolbutamide) were also found to be more effective and potent in the Kanslets compared rat islets 
or human native islets. In addition, Kanslets were found to be more sensitive to somatostatin, 
diazoxide and sodium azide (Ramachandran, Peng et al. 2014). The results of the study 
showed that Kanslets can be utilized as a secondary screening tool for drug discovery and drug 
testing procedures. 
In order to overcome the barrier of variability in islets from different donors, in Chapter 3 
experiments aimed to determine whether dose response curves of multi-donor Kanslets 
(created by mixing of islet cells from two different donors) to insulin secretagogues, and an 
inhibitor are equivalent to average dose response curves of the same two single-donor Kanslets 
tested individually. Dose response curve to two insulin secretagogues (glucose and 
glibenclamide) and one inhibitor (somatostatin) were evaluated for both multi- and single-donor 
Kanslets. 
1.6. Reaggregated hybrid Kanslets  
With the formation of multi-donor Kanslets, other cells can be incorporated into the 
Kanslets during reaggregation. Another important application of this approach is to improve 
culture conditions of pancreatic islets so that they can survive and function better in long term 
culture. Mesenchymal stem cells have helped maintain health of other cells in a variety of 






1.6.1. Mesenchymal stem cells (MSCs) 
Stem cells are defined as a class of cells with the ability to self-renew and differentiate. 
According to the development stage at which the cells are isolated, stem cells can be classified 
into embryonic, fetal, neonatal, and adult stem cells (Sandner, Prang et al. 2012). Ethical 
concerns and tumor formation are the major problems associated with embryonic and fetal stem 
cells (Nandoe Tewarie, Hurtado et al. 2009, Riazi, Kwon et al. 2009). Another class of stem 
cells called induced pluripotent stem cells, obtained by the reprogramming of differentiated adult 
stem cells, have also been shown to cause tumors (Scheper and Copray 2009, Masip, Veiga et 
al. 2010, Liu, Fu et al. 2011, Volarevic, Ljujic et al. 2011). Adult stem cells derived from adult 
tissue have the advantage of autologous transplantation which can help with immune rejection 
and also does not result in tumor formation (Nandoe Tewarie, Hurtado et al. 2009).  
MSCs can be derived from different adult tissues and have advantages as listed above. 
They were first discovered in the 1960s (Friedenstein, Piatetzky et al. 1966). MSCs can be 
isolated from bone marrow (Haynesworth, Goshima et al. 1992), adipose tissue (Zuk, Zhu et al. 
2002), dental pulp (Sakai, Yamamoto et al. 2012) and many other different tissues throughout 
the body (da Silva Meirelles, Chagastelles et al. 2006). MSCs can self-renew and differentiate 
into many different cell types like osteoblasts, chondrocytes, and adipocytes (Pittenger, Mackay 
et al. 1999, Chamberlain, Fox et al. 2007, Phinney and Prockop 2007).  
1.6.2. Properties of MSCs 
1.6.2.1. Regenerative and anti-apoptotic properties 
Studies have shown that MSCs can help reverse apoptosis of different cell types like 
cardiomyoblasts, neurons, and lung fibroblasts. The release of interleukin (IL)-6, insulin- like 
growth factor 1 (IGF1), vascular endothelial growth factor (VEGF), hepatocyte growth factor 




of apoptosis in different tissues. In particular MSCs have been shown to help with islets survival 
and function (Boumaza et al 2009, Lu et al 2010, and Park et al 2009). β-cell expression of anti-
apoptotic proteins increased when pancreatic islets were cultured with MSCs (Caja, Bertran et 
al. 2011, Lu, Lu et al. 2011). MSCs have been shown to reduce hyperglycemia by increasing β-
cell mass. Specifically all the diabetic animals administered a single injection of MSCs were 
shown to have significantly increased β-cell mass compared to animals not injected with MSCs. 
All these findings suggest that MSCs may help with regeneration of β-cells (Sordi, Malosio et al. 
2005, Lee, Seo et al. 2006).  
1.6.2.2. Angiogenic properties of MSCs 
Angiogenic properties of MSCs help in tissue repair and regeneration (Park, Kim et al. 
2010). MSCs promote endothelial cell migration and up-regulate the expression of angiopoietin 
and VEGF in endothelial cells (Zacharek, Chen et al. 2007). When cultures consisted of human 
islets and endothelial cells in the presence of MSCs, endothelial cells migrated to the islet’s 
surface. Islets with endothelial cells on their surface survived better and had improved insulin 
secretion (Johansson et al 2008). In the presence of MSCs endothelial cell density was higher 
in the transplanted islet graft.  MSCs secrete VEGF, fibroblast growth factor (FGF), 
angiopoietin-1 (Ang-1), TGF β, IL-6, IL-8, HGF, and platelet-derived growth factor, all of which 
help with revascularization. One study found that increased VEGF expression at the islet 
transplant site was associated with significantly increased graft survival and function (Kinnaird, 
Stabile et al. 2004). When diabetic mice were co-transplanted with pancreatic islets and MSCs, 
euglycemia was achieved within two weeks and graft showed enhanced expression of VEGF. 
MSCs also secrete matrix metalloproteases, which help host-derived endothelial cells to migrate 
into the islets. It has been suggested that MSCs may help with islet vascularization by initiating 
the formation of vessel-like structures through secretion of proteases that degrade the islet 




1.6.2.3. Anti-inflammatory and immune modulatory properties of MSCs 
MSCs secrete anti-inflammatory proteins and soluble factors to suppress the activity of 
immune cells like T and B lymphocytes, dendritic cells and natural killer cells (Chamberlain, Fox 
et al. 2007, Phinney and Prockop 2007). T lymphocytes are the main effectors of the immune 
response and play a prominent role in transplant rejection. MSCs secrete factors like 
indoleamine 2, 3-dioxyegnase (Li, Song et al.) TGF β1 and nitric oxide suppressing T cell 
proliferation (Di Nicola, Carlo-Stella et al. 2002, Aggarwal and Pittenger 2005, Sato, Ozaki et al. 
2007).  Matrix metalloproteinase (MMP) 2 and 9 secreted by MSCs also suppress T cells. When 
MMP 2 and 9 were blocked, MSCs could not suppress the T cell proliferation (Ding, Xu et al. 
2009). MSCs inhibit the proliferation of NK cells (Krampera, Cosmi et al. 2006) as well as alter 
the function of dendritic cells by inhibiting the production of tumor necrosis factor α (TNF α) and 
up-regulating the production of IL-10 (Jiang, Zhang et al. 2005). Finally, MSCs also inhibit β cell 
proliferation (Glennie, Soeiro et al. 2005, Agudelo and Iwata 2008). 
Therefore, in order to improve islet health during long term in vitro culture, in Chapter 4 
we chose to integrate MSCs during the process of reaggregation of islet cells and formed hybrid 
spheroids consisting of islet cells and MSCs. We determined cell composition, diameter, viability 
and insulin secretion of these hybrid clusters, and compared those to spheroids containing only 
islet cells or MSCs. 
1.7. Research Question 
The long term goal of our research is to better understand how bioengineered Kanslets 
can help advance the field of islet transplantation and diabetes research. Kanslets have 
previously been shown to be highly viable and functional. Kanslets have also been shown to 
reverse hyperglycemia in diabetic rats. The ability of pancreatic islet cells to self-reaggregate 




pancreatic islets into single cells, and then allowing them to reaggregate in a micromold for 3-5 
days. The purpose of this study was to optimize the experimental conditions for 
cryopreservation, drug testing, and islet transplantation procedures utilizing Kanslets. Success 
in all of these fields will greatly enhance the utilization of engineered islets for other applications 
such as drugs screening and transplantation. 
In Chapter 2, “A simplified method of long-term cryopreservation of human pancreatic 
islets based on reaggregation” we determined whether pancreatic islets could be cryopreserved 
as single cells and later reaggregated to form highly viable and functional Kanslets. We 
compared the outcomes (yield, immediate viability, metabolic function, insulin secretion and 
extended viability) after cryopreservation and thawing of pancreatic islets using our novel 
cryopreservation technique to the conventional one. We also transplanted cryopreserved 
Kanslets into diabetic rats and monitored their blood glucose levels. 
In Chapter 3 and 4, we examined the effect of creating hybrids using mixtures of cells, 
whether they were islet cells from different human donors, or cells from different tissues such as 
stem cells and islet cells. 
In Chapter 3, “Reaggregated human islet cells from different donors for drug testing” we 
focused on creating multi-donor Kanslets consisting of islet cells from different donors and 
compared the average dose response curve of insulin secretagogues and inhibitors between 
two single-donor Kanslets versus multi-donor Kanslets made from the same two donors. 
In Chapter 4, “Integration of islet cells and mesenchymal stem cells into spheroids 
improves viability but not long-term function” we created hybrid spheroids by reaggregating islet 
cells and mesenchymal stem cells (MSCs) in different proportions and studied their viability, 




In Chapter 5, we summarized all the findings from the work described here. We 
discussed the implication of this research to expand and/or advance research related to 
diabetes, drug discovery, and islet transplantation. In the last section of this Chapter we also 









A Simplified Method for Long-Term Cryopreservation of Human Pancreatic 






2.1. Abstract  
Preservation of pancreatic islets would be beneficial for islet transplantation to improve 
the treatment of diabetes. Unfortunately, current methods of islet cryopreservation have poor 
outcomes in terms of islet survival and function. In general, single cells have been shown to 
tolerate the cryopreservation procedure better than tissues/multicellular structures like islets. 
Thus, we optimized a method of cryopreserving single islet cells and, after thawing, 
reaggregated them into islet spheroids. Human pancreatic islets were either cryopreserved as 
whole native islets or as single cells. Cryopreserved single islet cells reaggregated into islet 
spheroids, termed Kanslets, efficiently within 3-5 days ensuing thawing. Approximately 79% of 
islet cells were recovered following single-cell cryopreservation protocol. Viability after long-term 
cryopreservation (4 weeks or more) was significantly higher in the cryopreserved; CP Kanslets 
(97.4±0.4%) compared to CP native islets (14.6±0.4%).  Moreover, cryopreserved Kanslets had 
excellent viability even after 7-10 days in culture (88.5±1.6%). Metabolic activity was 4- 5 times 
higher in CP Kanslets than CP native islets at 24 and 48 hours after thawing. Diabetic rats 
transplanted with CP Kanslets were normoglycemic for 10 months, identical to diabetic rats 
transplanted with fresh islets. However, the animals receiving fresh islets required a higher 
volume of transplanted tissue to achieve normoglycemia compared to the CP transplanted 
tissue. Using our novel method of cryopreservation, we achieved highly viable and functional 
islets after thawing. By optimizing the cryopreservation and thawing methods for pancreatic 






Over a million adults and children are living with type 1 diabetes in the US and every 
year approximately 30,000 new cases of type 1 diabetes are diagnosed (VanBuecken, Lord et 
al. 2000, 2010, American Diabetes Association 2014). After cerebral palsy and asthma, it is 
ranked as the third most common chronic disease in children and adolescence (Gage, 
Hampson et al. 2004). Treatment for people with type 1 diabetes consists of insulin injections 
multiple times a day. For those unable to control their blood glucose levels including those with 
diligent insulin treatment, islet transplantation is an alternative treatment (Shapiro, Lakey et al. 
2000). Until 2000, islet transplantation did not achieve much success. Only 10% of the patients 
who underwent islet transplants were insulin independent for 1 year (McCall and Shapiro 2012). 
With the advent of the Edmonton protocol in 2000, 7 patients were reported to have achieved 
insulin independence (Shapiro, Lakey et al. 2000). Since then, islet transplantation has been 
performed worldwide. A study in 2005 reported that approximately 70% of patients were insulin 
independent at 1 year after transplantation and the graft function was well maintained with 82% 
graft survival at 5 years (Ryan, Paty et al. 2005). 
Despite such advances, one of the major challenges for islet transplantation is the 
limited availability of the pancreatic tissue (Malek and Davis 2015), and the difficulty in 
predicting the health and function of the graft tissue prior to the transplant. With respect to the 
number of Americans suffering from diabetes, pancreas from only a few thousand deceased 
donors are available each year, and not all of those are suitable for transplantation, as they fail 
the criterion of selection or are destroyed during processing (National data. Organ Procurement 
and Transplantation Network website , Kandaswamy, Skeans et al. 2015). Hence, only a limited 
number of islet transplants can be performed each year. To further complicate the situation, in 
order to achieve normoglycemia, the islet volume must be greater than or equal to 9,000-11,000 




achieve that islet mass, islets from two or more donors are often needed, unlike other solid 
organ transplants, leading to greater inefficiencies (Naftanel and Harlan 2004, Froud, Ricordi et 
al. 2005, Shapiro, Lakey et al. 2005, Gangemi, Salehi et al. 2008). One of the major reasons for 
the multiple organ transplants is that the extraction of islets from the donated pancreas is not 
efficient and can cause stress on the islets during processing leading to low yield during the islet 
isolation process (Guignard, Oberholzer et al. 2004, Matsumoto, Noguchi et al. 2007). In 
addition to poor yield, which limits the number of islets available for transplant at any given time, 
the quality of the islets is difficult to judge in the short period of time available between receipt of 
the donor tissue and the scheduled transplant. Islets are typically transplanted within 48 hours 
after isolation from pancreas. Alternatively, islets may be cultured for an extended period of time 
so that multiple islet isolations can be performed, allowing for tissue to be pooled together once 
the sufficient number of islets collected for a single transplantation (Andersson, Borg et al. 
1976). During culture, quality assurance assays on donor islets are conducted (Andersson, Borg 
et al. 1976). Islets stored with short-term preservation techniques, such as standard tissue 
culture, have a limited life-span and face a high risk of contamination (Fraga, Sabek et al. 1998). 
Therefore, a method to efficiently store islets to provide time for quality control testing, and allow 
pooling of islets from different donors, for a single transplant procedure would be beneficial. 
Cryopreservation of pancreatic islets could offer a longer-term storage method. 
However, existing cryopreservation methods utilized are not optimal. Studies have reported 
reduced islet recovery (Lakey, Anderson et al. 2001, Lakey, Rajotte et al. 2001, Liu, Tian et al. 
2014), decreased viability (von Mach, Schlosser et al. 2003, Miranda, Mohan et al. 2013) and 
impaired or reduced insulin secretion (Janjic, Andereggen et al. 1996, Omori, Valiente et al. 
2007, Kenmochi, Asano et al. 2008) after thawing. Conventional cryopreservation protocols are 
based on slow freezing and rapid thawing of intact native islets. Native islets are complex 




mean diameter of 150µm and are densely packed, each islet containing approximately 1000-
10,000 cells (Bertram and Pernarowski 1998, Blodgett, Cura et al. 2014). In general, 
tissues/organs/multicellular structures are more difficult to cryopreserve than single cells (Hunt, 
Taylor et al. 1982). Heat transport limitations in tissues/multicellular structures lead to non-
uniform temperature changes between the cells in the core and those at the outer layer. 
Because of the slower rates of temperature changes in the core during cooling phase, cells 
placed interiorly loose water at a slower rate than the cells on the outer layer and hence there 
are more chances of intracellular ice formation during the cooling phase and more chances of 
recrystallization during the warming phase (Levin, Cravalho et al. 1977). Of all the injuries 
caused during the cryopreservation procedure, ice crystallization can be most damaging to the 
cells/tissues as it causes chemical as well as mechanical stress during cryopreservation 
(Bakhach 2009). Moreover, extracellular ice formed during the cooling phase can cause 
damage to cellular suspensions, but only by exerting compressive forces on the cells, whereas 
in multicellular structures, extracellular ice forms within the three dimensional structure and can 
be detrimental to the tissues (Pegg 2007). Additionally, the inner and outer layer of cells may be 
exposed to different concentrations, and duration of DMSO. Previous publications have reported 
that intact pancreatic islets take a longer time to equilibrate with the cryoprotectant than 
individual islet cells, and in intact native islets equilibration times are dependent on the islet size 
(Benson, Liu et al. 1993, Benson, Benson et al. 2014). 
It is critical to develop an effective method of islet cryopreservation that would yield 
highly viable and functional islets so that islet transplantation becomes a more feasible 
treatment option for people with diabetes. However, multicellular structures like islets pose 
multiple barriers towards successful cryopreservation. Therefore, we developed a new method 




study compares the outcomes of a novel cryopreservation technique to the conventional method 
following long-term cryopreservation. 
2.3. Methods 
Tissue procurement and group descriptions 
Native human pancreatic islets were ordered from the National Institutes of Health - 
Integrated Islet Distribution Program (IIDP). Pancreatic islets from human donors with obesity, 
diabetes or any other metabolic disorders were not included in the study. Only islet preparations 
with high purity (>85%) were included. As the islets were received, they were placed in tissue 
culture plates containing islet medium consisting of Connaught Medical Research Laboratories 
1066 (CMRL; cat. no. MT5110CV; Thermo Fisher Scientific; Chicago, Illinois) medium 
supplemented with 10% fetal bovine serum (FBS; cat. no. 26140079; Thermo Fisher Scientific), 
1% antibiotic/antimycotic (cat. no. 15240062; Thermo Fisher Scientific) and 1% glutamax (cat. 
no. 35050061; Thermo Fisher Scientific) and allowed to recover for 24 hours in an incubator at 
37ºC and 5% CO2. After 24 hours in culture, islets were divided into the native islet group (fresh 
or cryopreserved (CP)) or the reaggregated islet clusters, called the Kanslet group (fresh or 
CP).  
Dissociating islets into single cells 
Islets in the Kanslet groups were dispersed into single cells according to our previously 
published protocol (Williams, Wang et al. 2009). In short, islets were placed in a 50 ml tube and 
centrifuged at 1209 g for 5 minutes and the supernatant was discarded. The islets were washed 
twice with calcium and magnesium-free Hank’s Balanced Salt Solution (cmf-HBSS). 
Subsequently, the digestion medium consisting of cmf-HBSS and 5 units/ml papain 
(Worthington, Lakewood, NJ) was added and the suspension was incubated on a rotator at 




stopped using culture medium containing calcium and magnesium. The cells were then washed 
twice with islet medium to remove the papain.  
Seeding single cells in the micromold to form Kanslets 
Single cells were seeded into the micromold as described in our previously published 
protocol (Ramachandran, Williams et al. 2013). In short, fresh or cryopreserved single cells, in 3 
ml of islet medium were carefully plated into the micromold. Cells were allowed to settle into the 
wells of the mold for several minutes. The micromold was incubated at 37ºC and 5% CO2. The 
cells self-reaggregated and formed Kanslets within 3-5 days. The culture media was changed 
every 24 hours.  
Cryopreservation of single cells 
For CP Kanslets, commercially-available products common for cryopreservation of other 
types of single cells were utilized. CryoStor CS10 (cat. no. C2874; Sigma-Aldrich, containing 
10% dimethyl sulfoxide (DMSO)) has been used to cryopreserve different types of single cells to 
achieve better post-thaw results (Clarke, Yadock et al. 2009, Fortin, Azari et al. 2016). In detail, 
single cells were centrifuged at 1209 g for 5 minutes to form a pellet, and supernatant was 
removed. Cells were dispersed in 1 ml of CryoStor CS10 containing 10% DMSO, transferred to 
a 2ml cryovial and slowly cooled down at -1ºC/ minute. In order to accomplish the slow cooling, 
single cells in a cryovial were placed in a CoolCell (cat. no. BCS-405; Biocision; San Rafael, 
CA) at -80ºC. After 15-20 minutes, nucleation was performed to release the latent heat of fusion 
by mechanical agitation and returned to -80ºC for 15 hours. Samples were then stored in liquid 
nitrogen at -196ºC. At the time of thawing, cells were rapidly heated in a water bath at 37ºC for 
approximately 2 minutes until the last ice crystal melted. The sample was then diluted with fresh 
islet medium. Cells were centrifuged at 1209 g for 5 minutes, fresh medium was added, and 




CP Kanslets. Once CP Kanslets have reaggregated, they were transferred to a petri dish with 
fresh islet medium. 
Cryopreservation of native islets 
There are no effective commercial products available to CP native islets, however 
various recommendations are provided in the literature with regard to cryopreservation. Keeping 
this in mind, pilot studies were carried out to determine the optimal cryopreservation conditions. 
Media tested included CMRL and Rosewell Park Memorial Institute (RPMI; cat No.11875093; 
Thermo Fisher Scientific) with and without curcumin (cat No. 458-37-7; Sigma-Aldrich) and zinc 
sulfate (cat No. 744620-0; Thermo Fisher Scientific). DMSO concentrations tested were 10% 
and 14%. Different equilibration times with DMSO included either adding DMSO in one step 
(incubated for 15 minutes in final concentration of 10% or 14% DMSO after single addition) or 
adding DMSO in a stepwise manner to get the desired final concentration of DMSO. Native 
islets were cryopreserved as intact islets according to Lakey’s protocol as described in the 
literature (Lakey, Anderson et al. 2001) with some modifications. In short, native islets were 
centrifuged, and dispensed in media containing RPMI with curcumin (10µM) and zinc sulfate 
(16.8µM), and the sample was incubated with DMSO added in a stepwise increasing manner 
(incubated at 22ºC, first in 5% DMSO for 5 minutes, then in 7% DMSO for 25 minutes and, 
finally at final concentration of 10% for 15 minutes). Islets were moved to an ice bath at 4ºC for 
15 minutes and then to an ethanol bath and nucleation was performed at -7ºC. After storing the 
samples in a CoolCell overnight (cools samples at -1ºC/ minute), samples were moved to -
196ºC in liquid phase nitrogen. When thawing, samples were rapidly thawed at 37ºC in a water 
bath and DMSO was removed by stepwise sucrose dilution. 0.75 M sucrose solution was added 
for 30 minutes at 0ºC and then culture medium was added every 5 minutes over a period of 20 
minutes. The suspension with CP islets was centrifuged at 1209g for 5 minutes and incubated 




to recover for 24 hours before they were assessed for viability, tissue recovery, metabolic 
function and glucose-stimulated insulin secretion (GSIS).  
While optimizing the cryopreservation conditions, native human islets and single cells 
were cryopreserved for 1 week while for all other experiments native islets and single cells were 
cryopreserved for a minimum of 4 weeks. 
Viability 
Cell death was analyzed using YO-PRO-1 and propidium iodide staining (cat. no. 
V13243; Thermo Fisher Scientific). YO-PRO-1 stain selectively passes through the plasma 
membranes of apoptotic cells and labels them with green fluorescence. Necrotic cells are 
stained red with propidium iodide (Gawlitta, Oomens et al. 2004). 1 µl of YO-PRO-1 and PI each 
were added to 200µl of media containing fresh or CP native islets/Kanslets. Images were taken 
using an Olympus FluoView 300 confocal microscope. Later the images were analyzed using 
Abode Photoshop CS 5 Extended. Total islet pixel number as well as the pixel numbers for the 
red and green staining of native islets/Kanslets was calculated. In order to calculate the 
percentage of apoptotic and necrotic cells, pixel numbers for green, and red staining were 
divided by the total pixel numbers of native islet/Kanslets and multiplied by 100. The proportion 
of live cells was defined as the islet area lacking green/red staining. Immediate viability was 
assessed at 24 hours while extended viability was assessed at 7-10 days in culture.  
Immunofluorescence Staining 
To analyze the proportion of α-, β- and δ- cells in the fresh and CP Kanslets, the 
spheroids were stained for insulin (β), glucagon (α) and somatostatin (δ) as described in our 
previously published protocol (Ramachandran, Williams et al. 2013). First, the fresh and CP 
Kanslets were washed in phosphate buffered saline (PBS) 3 times for 5 minutes each. 




Kanslets were washed in PBS again 3 times for 5 minutes each and incubated for 2 hours at 
room temperature with primary antibodies against insulin (1:100; cat no. ab7842; Abcam; 
Cambridge, MA), glucagon (1:300, cat no. 10988, Abcam) and somatostatin (1:300, cat.no.  
ab53165, Abcam). After incubating with primary antibody, samples were washed with PBS 3 
times for 5 minutes each, followed by incubation in a mix of fluorophore conjugated secondary 
antibodies consisting of DyLight 488 (1:400, cat. no. 706-485-148Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA), Alexa 555 (1:400, cat. no. A31570; Thermo Fisher 
Scientific) and Alexa 647 (1:400; cat. no. A31573; Thermo Fisher Scientific) in a dark wet 
chamber for 1 hour. After incubation with secondary antibodies, samples were washed with PBS 
3 times for 5 minutes each and mounted on microscopic slides with anti-fading agent Gel/Mount 
(Biomeda, Foster City, CA). The following solution was used to dilute primary and secondary 
antibodies: 1% BSA, 0.03% Triton X-100 and PBS. Images were captured on a Nikon C1Si or 
C1 Plus confocal microscopes. For cell composition analysis, the relative proportion of α-, β-, or 
δ-cells in each islet was evaluated by counting the number of individual types of cell and 
dividing it by the total sum of endocrine (α-, β-, and δ-) cells per islet and multiplying by 100. 
Image J was utilized to perform cell composition analysis.  
Metabolic function 
Metabolic function was assessed by using the AlamarBlue assay (DAL 1100; Thermo 
Fisher Scientific). The active ingredient present in the AlamarBlue assay is resazurin, which is 
permeable through the cell membrane. The fluorophore acts as an intermediate electron 
acceptor in the electron transport chain. Fluorescence intensity was measured in a microplate 
reader at an excitation wavelength at 530 nm and an emission wavelength at 590 nm 
(Rampersad 2012). In our study, AlamarBlue dye was added to the culture media (10% volume) 
containing known volumes of native islets or Kanslets and the fluorescence reading was taken 




hours. Islet equivalents (IEQ) were used to normalize the fluorescence readings. Control wells 
consisted of culture media and the AlamarBlue dye without the Kanslets or native islets.  
Glucose stimulated insulin secretion; GSIS 
For static incubation, CP native islets/ Kanslets were handpicked with a micropipette and 
distributed in 96 well plates containing 100 µl of Earle's balanced salt solution (EBSS) with 
1.4mM glucose. CP native islets/ Kanslets were subjected to different glucose concentrations 
(1.4mM, 22.4mM, and 22.4mM +KCl) for an hour. Each dose was tested in quadruplets. After 
60 min of static incubation at 37ºC and 5% CO2, conditioned media samples were collected and 
frozen at -80ºC until quantification using a human insulin enzyme linked immunosorbent assay 
(ELISA; cat. no. 80-INSHU-E10.1; Alpco; Salem, NH) was performed. During the time of 
quantification, standards as well as samples were added to the insulin specific monoclonal 
antibody coated microplate wells. Samples and standards were incubated with the detection 
antibody for an hour, the plates were washed with the wash buffer.  Incubation was again 
carried out for 15 minutes after adding the substrate. The stop solution was added and optical 
density was measured at 450nm by a SpectraMax M5 Microplate Reader. Optical density 
values were divided by the respective number of IEQ’s in each well for normalization.  
Isolation of rat pancreatic islets 
Pancreatic islets were isolated according to our published protocol (MacGregor, Williams 
et al. 2006, Williams, Wang et al. 2009, Williams, Huang et al. 2010), which was approved by 
the Institutional Animal Care and Use Committee. In brief, Sprague Dawley (SD) rats (Harlan; 
Indianapolis, Indiana) were anesthetized by intraperitoneal injection of ketamine (80 mg/kg; 
Vedco; St. Joseph; MO) and xylazine (10mg/kg; Lloyd Laboratories; Walnut, CA). The 
peritoneal cavity was opened and pancreatic main duct to the duodenum was clamped and 




Lakewood, NJ). The pancreata were excised and incubated with gentle rotation for 20–30 min in 
a 37ºC incubator. Pancreata were washed and strained through a 500µm mesh screen, and the 
contents were suspended in a 3:1 mixture of Histopaque 1077 and 1119 (density = 1.1085; Cat. 
No. 11191 and 10771; Sigma Aldrich; St. Louis, Missouri) and centrifuged beneath a layer of 
HBSS supplemented with 5% Bovine Calf Serum (BCS, Cat. No. SH3007303; GE Healthcare 
Lifesciences; South Logan, Utah).The islets, collected from the gradient, were sedimented and 
washed with HBSS supplemented with 5% BCS over a sterile 40-mm mesh cell strainer. Islets 
were placed into islet medium and allowed to recover for 24 hours in an incubator at 37ºC and 
5% CO2. 
Rat islet transplantation 
SD rats were injected with streptozotocin (55mg/kg; Sigma Aldrich), which induced 
diabetes 1 week prior to the surgery. During that week, their blood glucose was measured daily 
and animals were treated with long acting insulin (Lantus, 1-2 units/kg; SANOFI; Bridgewater, 
NJ) when glucose rose above 400mg/dl. Immediately prior to transplantation, animals were 
given ketamine (80 mg/kg; SANOFI)/ xylazine (10mg/kg; Lloyd Laboratories) and allowed to 
quiet. The surgical site was shaved with clippers and scrubbed with betadine (Medline; 
Mundelein, IL)/chlorhexidine (Xttrium Laboratories, Inc., Mount Prospet IL), followed by 10% 
povidone/iodine solution with a final wash of sterile warm saline. The animals were kept on an 
isoflurane vaporizer during surgery. An incision was made in the skin followed by a short upper 
abdominal incision of the linea alba to visualize the stomach/duodenal area. The stomach was 
grasped with blunt forceps and gently pulled through the incision. A non-adherent pad was 
moistened with warm saline, and placed beneath the omental area, and the omentum was 
gently expanded using forceps. CP Kanslets and fresh native islets (with two different IEQ 
ranges) were placed into the rat omentum using a hydrogel (HyStem-C, ESI Bio; Almeda, CA) 




base layer of hydrogel was applied to the omentum surface and allowed to solidify. The 
Kanslets were mixed with more hydrogel and placed near the omentum vascularization on top 
of the base layer. After the gel solidified, the omentum was rolled and tacked in 2-3 places 
against the stomach using 5-0 prolene blue monofilament with RB-2 taper needle (AD Surgical; 
Sunnyvale, CA). The stomach/ omentum was gently placed in the abdominal cavity. Sterile 
warm saline was added to the cavity. The abdominal muscle was closed with simple interrupted 
technique using 3-0 braided polyglactin suture with a SH-1 taper needle. The skin was closed 
using a subcuticular pattern with buried knots using 4-0 braided polyglycolic acid with a reverse 
cutting P3 needle (AD Surgical), using the similar procedure as described.  
Immediately after surgery, analgesia (Meloxicam, 2mg/kg; Norbrook Laboratories; 
Lenexa, Kansas) was given. The animals were placed under a heat lamp to allow the body 
temperature to rise for better recovery from the anesthesia. Rats were monitored daily and 
analgesia was given for up to 48 hours after surgery. Blood glucose was checked daily and 
long-acting insulin (Lantus 0.2 units/kg; SANOFI) was given until the blood glucose levels 
normalized. Once the blood glucose stabilized, daily checks were reduced to 3 times /week, and 
eventually to weekly, as appropriate.  
Data Analysis 
SigmaPlot software was used for data analysis. To determine significance between 
group differences for immediate viability, metabolic function, and extended viability, a student t-
test was used. To determine the significance within group differences for immediate viability, 
extended viability, and GSIS, a one-way ANOVA was performed. An alpha level of 0.05 was 
utilized to determine the significance of these findings. All the values were expressed as 






Testing for optimal short-term cryopreservation conditions of native islets and Kanslets 
Optimal cryopreservation conditions of native islets as well as Kanslets were determined 
based on the results of the viability assessment after testing them with different conditions. 
Native islets were assessed for their viability after cryopreserving them with different 
percentages of DMSO, different equilibration times, and different media with additives. Kanslets 





Figure 6. Viability of fresh and short-term CP Kanslets.  
Fresh Kanslets were formed by self reaggregation of freshly dispersed single islet 
cells and CP Kanslets were formed by self reaggregation of CP single islet cells 
after thawing. There was no significant difference in the percentage of viable and 
dead (apoptotic and necrotic) cells between fresh Kanslets and CP Kanslets after 1 
week of cryopreservation. All values are expressed as average ± standard error 




Single islet cells were cryopreserved using a standard protocol designed for multiple cell 
types employing CryoStor solution with slow cooling and rapid thawing. After thawing, 
immediate viability was near 80% (Figure 6) and was not significantly different than fresh 
Kanslets. Likewise, the number of apoptotic or necrotic cells was low and there were no 
statistical differences in the percentages after cryopreservation compared to their fresh state. 
For native islets, there was no standard protocol for cryopreservation so a series of 
optimization experiments were undertaken. First, using the step-wise cooling method, two 
different DMSO concentrations (10% and 14%) were compared. Both cryopreserved groups had 
reduced viability with respect to the fresh native islets, and the percentage of DMSO had no 
effect on the viability outcome (Figure 7A). Thus, next set of optimization studies were 
conducted using the lower DMSO concentration at 10%. When the one-step cooling method 
was compared to the step-wise method on native islets, there was a significant decrease in the 
percentage of viable and increase in percentage of dead cells (apoptosis and necrosis) using 
the one-step protocol (Figure 7B). A single addition of DMSO at the desired final concentration 
of 10% resulted in a low a viability of 32.4± 5.9%. In contrast, the step-wise addition of DMSO 
resulted in significantly higher viability. However, both cryopreserved groups had significantly 
lower viability than the fresh native islets (Figure 7B). Based on this additional finding, the step-
wise addition of 10% DMSO was used in the next set of experiments. The final optimization step 
was to test different media during the cryopreservation process. Again, viability of the groups 
cryopreserved using all the different media was significantly less than fresh native islets. There 
was no significant difference between the viable cells obtained after cryopreservation with 
different media. However, cryopreservation with the medium containing RPMI with curcumin 
and zinc sulfate resulted in higher proportion of viable cells (Figure 7C) with respect to the other 




subsequent experiments with native islets used media containing RPMI with curcumin and zinc 










Figure 7. Optimization of cryopreservation conditions for native islets.  
In all the tested conditions, fresh native islets had significant higher proportion of viable cells 
than the CP native islets. A) Viable and dead cells after short-term cryopreservation using 
different percentages of DMSO showed no difference between the 2 DMSO concentrations. 
B) Fresh native islets had a significantly higher proportion of viable cells than CP native 
islets in both the tested conditions. There were significantly higher percentage of viable with 
fewer dead (apoptotic and necrotic) cells when DMSO was added stepwise rather than a 
one-step protocol. C) Fresh native islets had a significantly higher proportion of viable cells 
than CP native islets in all 4 the tested conditions (indicated by *). The best results were 
obtained with cells in RPMI media enhanced with curcumin and zinc sulfate, compared to 
CMRL media with and without the same additive. All values are expressed as average ± SE. 










After optimizing islet cryopreservation using a short-term preservation protocol (1 week 
cryopreservation), the procedures were utilized to test the outcomes for long-term 
cryopreservation (4 weeks and longer). Figure 8A illustrates the non-uniform size and shape of 
the long-term cryopreserved native islets, as compared to the single cells that were 
cryopreserved and subsequently formed into CP reaggregated Kanslets after the thawing 
process. Some native islets showed a loss of structural integrity and dark cores, indicative of 
areas of cell death. The right image (Figure 8A) shows CP Kanslets formed by self- 
reaggregation after thawing. CP Kanslets were highly viable and uniform in size. 
Cryopreservation had no effect on the ability of the islet cells to self-aggregate.  
Tissue recovery 
After having optimized the cryopreservation procedures for single cells and for intact 
islets for 1 week of storage, the outcome of these techniques was tested for longer-term 
cryopreservation (4 weeks and longer). Tissue recovery after long-term cryopreservation for the 
native islet group was based on the islet volume (measured by IEQ) recovered after thawing. 
Approximately 75% of native islets were recovered after thawing. Tissue recovery for CP 
Kanslets was measured by the single islet cells recovered immediately after thawing. On 
average, there was nearly an 80% recovery of single islet cells, with no difference between the 
two groups (Figure 8B).  
Metabolic function 
Interestingly, there was a significant difference in metabolic function of CP native islets 
and CP Kanslets at 24 hours as well as at 48 hours (Figure 8C). CP Kanslets were 4 to 5 times 
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Figure 8. Morphology and tissue recovery after long-term cryopreservation of native 
islets and CP Kanslets.  
A) CP native islets and CP Kanslets after thawing within 24 hours in culture. Left image 
shows typical CP native islets after thawing. Some native islets showed loss of structural 
integrity and dark cores, indicative of areas of cell death. The right image shows CP 
Kanslets formed by self reaggregation after thawing. CP Kanslets were highly viable and 
uniform in size. (Scale bar= 100µm). B) There was no significant difference in the proportion 
of tissue recovered between native islets (calculated by the percent recovery of IEQs) and 
CP Kanslets (calculated by the percent recovery of the number of islet cells). All values are 
expressed as average ± SE. n=2 to 5 CP replicates. C) ATP metabolism/ IEQ of CP native 
islets and CP Kanslets at 24 and 48 hours post thaw show that the CP Kanslets had 4- 5 
times higher metabolic function than CP native islets at both time points (indicated by * and 
#). All values are expressed as average ± SE. n= 6-22 islets/Kanslets per group, p< 0.05. 









Viability of all native islets, and Kanslets before and after long-term cryopreservation was 
assessed for apoptosis, and necrosis. Figure 9A illustrates representative images from both the 
native islet and Kanslet groups before and after cryopreservation. Red, and green in the images 
indicate cell death from necrosis, and apoptosis, respectively. The grey areas indicate regions 
of viable cells. Viability was high for native human islets prior to long-term cryopreservation with 
only a few dead cells on the surface (87.1±2.0%). However, after thawing, native islets had 
extensive cell death from apoptosis as indicated by the saturated green values (14.6±4.1%), 
which is in contrast to the short-term cryopreservation results shown in Figure 7. 
Kanslets made from fresh or cryopreserved cells both demonstrated high viability. 
(95.6±0.4% and 97.4±0.4% respectively). There was a significant increase in the percentage of 
apoptotic cells before and after long-term cryopreservation of native islets, but not for the 
Kanslets (Figure 9B). Due to the fact that the majority of cells in the intact native islets after 
long-term cryopreservation were dead, it was impossible to continue with experiments requiring 
longer culture. Therefore, only fresh and CP Kanslets were monitored to determine long-term 
survival in culture. Figure 9B summarizes the results showing that the immediate and extended 
viability of CP Kanslets was 97.4±0.4% and 88.5±1.6% respectively. There was no difference in 
the percentage of viable cells between fresh and CP Kanslets at 24 hours. However, there was 
8% more decline in viable cells in the cryopreserved group compared to the fresh Kanslets with 








Figure 9. Viability of native islets and Kanslets before and after cryopreservation.  
A) Representative islets from the native islets and Kanslets group before and after 
thawing. Gray areas indicate live cells, whereas red and green indicates cell death 
through necrosis and apoptosis, respectively. B) The percentage of viable and dead 
(apoptotic and necrotic cells) cells before cryopreservation and after thawing of native 
islets and Kanslets. There was a significant decline in the percentage of viable cells and 
significant increase in the percentage of dead (apoptotic and necrotic) in the native islets 
after thawing (indicated by * and #), whereas CP Kanslets were as viable as fresh 
Kanslets. Extended viability after 7-10 days in culture had a significant decline in the 
viability of CP Kanslets (indicated by & and @) with respect to viability at 24 hours in 
culture and also with respect to extended viability of fresh Kanslets. Approximately 50-200 












Islet cell composition 
Immunofluorescence staining was performed on fresh and long-term CP Kanslets to 
examine the proportion of β-, α- and δ-cells in the islet spheroids. No significant differences 
were found for each cell type between the fresh and CP groups. β-cells made up a majority of 
the cell types in fresh Kanslets as well as in CP Kanslets. The other endocrine cell types 
appeared to be randomly dispersed throughout the Kanslets (Figure 10A). α-cells were the 
second most prevalent cell type in fresh Kanslets as well as CP Kanslets. Somatostatin-positive 
δ-cells made up the smallest percentage of cells in fresh Kanslets and in CP Kanslets and there 
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Figure 10. Islet cell composition of fresh and CP Kanslets.  
A) Representative immunofluorescence images of fresh and CP Kanslets. Green 
represents β-cells (insulin positive), red represents α-cells (glucagon positive) and blue 
represents δ-cells (somatostatin positive). B) There was no significant difference in the 
islet cell composition of β-, α- and δ- cells between fresh and CP Kanslets. 30-35 Kanslets 





Glucose stimulated insulin secretion (GSIS) 
For GSIS, CP Kanslets and CP native islets were challenged with increasing 
concentrations of glucose (1.4mM, 22.4mM and 22.4mM with KCl) and the insulin secretion 
measured. Cell death in the long-term CP native islets was too high to measure insulin secretion 
after freezing; hence we only have insulin secretion data for the extended CP Kanslets. Figure 
11 shows the amount of insulin secreted by CP Kanslets at different concentrations of glucose. 
Although there was no statistical significant difference between the insulin secretion values at 
different glucose concentrations due to the variability in responses at the higher concentrations, 




Figure 11. Glucose-stimulated insulin secretion of long-term CP Kanslets.  
Insulin secretion was measured after CP Kanslets were exposed to low glucose 
(1.4mM), high glucose (22.4mM) or high glucose with depolarization (22.4mM +KCl). 
Although not significant, CP Kanslets demonstrated increased insulin secretion with 
increasing glucose concentrations. n=5, each n here represents 1 human donor with 4 




Viability of rat CP Kanslets 
In order to determine whether CP Kanslets had benefit in a transplantation model, 
quality control experiments were repeated on the rat islets to be used in the transplant. 
Dispersed single cells from SD rat pancreatic islets were cryopreserved using the same protocol 
described in the methods section for human pancreatic islet cells. The rat CP Kanslets were 
greater than 95% viable. In fact, long-term CP rat Kanslets were 18% more viable than the 





Figure 12. Viability of rats Kanslets after cryopreservation.  
Rat single islet cells were cryopreserved using the same protocol described for human 
islet cells. CP rat Kanslets formed after cryopreservation and thawing of rat islet cells 
were significantly more viable and had fewer dead cells (indicated by * and #) than fresh 
native islets used to create CP Kanslets. Approximately 30-35 native islets/ Kanslets 








Rat islet transplantation 
In order to determine whether the CP cells could function in a transplant situation, SD rat 
pancreatic islet cells that had been cryopreserved for 1-4 months were thawed, formed into CP 
Kanslets, and transplanted into diabetic rats. Diabetic rats transplanted with fresh native islets 
were used as controls. In order to determine the minimum amount necessary to reverse 
hyperglycemia, we first transplanted each diabetic rat with 5000-8500 IEQ/kg body weight of 
either fresh native islets or CP Kanslets. The average blood glucose levels pre-transplantation 
was approximately 390 mg/dl for both groups. Rats had an average blood glucose levels of 330 
mg/dl during the first month after transplantation with fresh native islets, indicating that the low 
volume of transplanted islets failed to restore normoglycemia (Figure 13A). As fresh native islet 
failed to reverse hyperglycemia, the rats were euthanized and on termination the average blood 
glucose level was 479±26.96 mg/dl. In contrast, rats transplanted with similar IEQ of CP 
Kanslets had an average blood glucose of 150 mg/dl during the first month after transplantation, 
and rats remained non-diabetic for 10 months following transplantation (Figure 13B). At 
termination the average blood glucose levels of rats transplanted with CP Kanslets was 
111.5±17.50 mg/dl. As 5000-8500 IEQ of native islets failed to reverse hyperglycemia, we 
subsequently transplanted diabetic rats with higher IEQs (10000-12000 IEQ/kg body weight) of 
fresh native islets. After transplantation, the average blood glucose of animals was 142 mg/dl 
during the first month. Rats maintained normoglycemia during the 10 month period. Animals 
transplanted with 10000-12000 IEQ/kg body weight of fresh native islets and animals 
transplanted with approximately 8500 IEQ/kg body weight of CP Kanslets not only were 
normoglycemic for 10 months but these group of animals also achieved normoglycemia within 
24 hours of transplantation (Figure 13B).  
Figure 10B: GSIS of fresh Kanslets and CP Ka 
 
 








Figure 13. Transplantation of fresh native islets and long-term CP Kanslets into 
diabetic rats.  
A) Transplantation of fresh rat native islets (10000-12000 IEQ/kg body weight) and rat CP 
Kanslets (8500 IEQ/kg/body weight) lowered the blood glucose levels of diabetic animals. 
Normoglycemia could not be achieved in animals transplanted with 5000-8500 IEQ/kg 
body weight of fresh native islets within the first month after transplantation, hence animals 
in this group were euthanized.  B) In the other 2 groups normoglycemia was achieved 
within the same day after surgery. Average blood glucose values show that normoglycemia 
was maintained until the rats were sacrificed at 10 months and blood glucose values of rats 
transplanted were below 200mg/dl at any given day after transplantation in both the 
successful groups. For long-term studies, N=2 rats/group [fresh native islets (10000-12000 
IEQ/kg body weight) and CP Kanslets (8500 IEQ/kg/body weight)], N=3 [fresh native islets 







Historically, cryopreservation of tissues has been challenging because of the stresses 
put on the tissue during the freezing process. In order to avoid non-uniform cooling, and 
warming and to minimize damage caused by extracellular ice formation, we cryopreserved 
pancreatic islets as single cells, and after thawing, reaggregated islets cells in micromolds to 
form CP Kanslets. We compared the outcomes of our single-cell cryopreservation protocol to 
the conventional protocol using intact native islets.  
Previous studies have reported the reduced viability and function of intact pancreatic 
islets post-cryopreservation. Due to some of these poor results reported previously, process 
optimization suggestions have been made in the literature. We tested various suggestions alone 
and in combination to ensure that CP intact islets would yield the best possible outcomes after 
thawing. Reactive oxygen species are a major contributor towards cell death of different cell 
types during the cryopreservation procedure (Yard, Beck et al. 2004, Bucak, Atessahin et al. 
2007). Curcumin has antioxidant properties (Liu, Chen et al. 2016) and in cryopreservation has 
been shown to improve islet viability and function(Kanitkar and Bhonde 2008). Additionally, zinc 
sulfate protects against deoxyribonucleic acid (DNA) damage during the cryopreservation 
procedure (Kotdawala, Kumar et al. 2012). Hence, during the optimization of the conditions of 
native islets, we chose to test the effects of curcumin, and zinc sulfate on viability of native islets 
after thawing. Even after mixing additives like curcumin and zinc sulfate and following published 
cryopreservation protocols with slight modifications, we continued to have significant levels of 
cell death in native islets after long-term cryopreservation. We identified less than 20% viable 
cells in native islets after 4 weeks of cryopreservation. That low viability is in contrast to the 60% 
viability that we measured using the same protocol for only 1 week. There is a possibility that 
even longer duration of storage might have resulted in greater decline in the viability of native 




weeks. Out of those, many studies did not assess viability as one of their outcomes after 
thawing (Piemonti, Bertuzzi et al. 1999, Li, Xue et al. 2011, Xue, Luo et al. 2011). Additionally, 
studies reporting high viability post-cryopreservation have cryopreserved the native islets for 
around 1 week or failed to report the duration of cryopreservation (von Mach, Schlosser et al. 
2003, Omori, Valiente et al. 2007). Only a few of studies have cryopreserved islets for more 
than a month. One recent study looked at islets that were cryopreserved for 16 years, and 
reported no differences in the proportion of apoptosis before and after cryopreservation but 
found only partial in vivo function of islets after thawing (Manning Fox, Lyon et al. 2015). To the 
best of our knowledge, the only other study that cryopreserved pancreatic islets for 3 months, 
which used the University of Wisconsin cryopreservation media along with ascorbic acid-2 
glucoside, found that the highest viability achieved was around 68% (Arata, Okitsu et al. 2004).  
As the native islets in our study had poor viability after long term cryopreservation, we 
chose not to freeze islets as intact and whole, but rather took the approach of freezing the cells 
individually. Single cells in our study were cryopreserved for 1- 6 months, a comparatively 
longer freezing period than most of the previous studies preserving intact islets. Even with a 
longer storage period, we obtained reaggregated CP Kanslets that were more viable as 
compared to CP native islets. In contrast to the significant loss of viability in the native islets 
after long-term cryopreservation, the new method of cryopreservation described here using 
single cells resulted in approximately 98% viable tissue after long-term cryopreservation. 
Further viability of CP Kanslets after 7-10 days in culture was still approximately 90%, which is 
much higher than what previous studies have reported (Miranda, Mohan et al. 2013).  
Recovery of islets after cryopreservation, often referred to, as yield, has been shown to 
have great variability depending on the study, with values ranging from approximately 55-75% 
(Sandler, Kojima et al. 1986, Lakey, Rajotte et al. 2001, Liu, Tian et al. 2014) and few studies 




islets was 75%, which is similar to the results of the other laboratories (Lakey, Anderson et al. 
2001). Following our novel cryopreservation protocol, recovery of islets cells after thawing was 
above 80%, comparable to other highly successful approaches. 
Only one other study examined islet cryopreservation to the extent reported here 
including islet recovery, islet morphology, and both in vitro and in vivo function (Piemonti, 
Bertuzzi et al. 1999). In the study by Warnock et al., when DMSO was added in a stepwise 
manner, it was found that the basal insulin secretion was higher in cryopreserved islets than the 
fresh ones, but the responsiveness to a glucose challenge decreased after cryopreservation. 
Glucose control was also lost when these islets were transplanted into diabetic mice. Other 
studies have also reported decreased insulin secretion after cryopreservation (Janjic, 
Andereggen et al. 1996, Omori, Valiente et al. 2007, Kenmochi, Asano et al. 2008). In our study, 
CP Kanslets also demonstrated a blunted response to increasing glucose concentrations. 
However, more importantly, when transplanted into diabetic rats, they completely reversed the 
diabetes in less than 24 hours. In a similar study, blood glucose values returned to normal only 
after 7 days post transplantation (Ohnishi, Murakami et al. 2012). Most importantly, previous 
publications examining the ability of CP intact pancreatic islets to reverse diabetes after islet 
transplantation have followed only short-term success. When CP islets cultured with sertoli cells 
were transplanted into diabetic animals, graft survival averaged 35 days (Li, Xue et al. 2011) in 
contrast to our 300 days. Other studies also reported that normoglycemia could be maintained 
only for 3-5 months after transplantation (Nakagawara, Kojima et al. 1981), whereas in our rats 
transplanted with CP Kanslets were normoglycemic for 10 months until sacrifice. 
Finally, one of the previous studies reported transplanting approximately 13,000 IEQ/ kg 
body weight of CP islets to reverse hyperglycemia (Lakey, Warnock et al. 1996).  In another 
study that failed to reverse hyperglycemia after transplantation, an extremely large amount of 




al. 2015). In contrast, we were able to achieve long-term normoglycemia while transplanting 
only 8,500 IEQ/ kg body weight of CP Kanslets, which was even less than the IEQ required to 
reverse hyperglycemia when animals were transplanted with fresh native islets in our study. 
Results of this study showcase that small amounts of CP Kanslets can provide for quick return 
to normoglycemia post transplantation and CP Kanslets maintained their long-term functionality 
as compared to the best cases in the literature.  
2.6. Conclusion 
Our study demonstrated that using the single-cell cryopreservation protocol, it is possible 
to obtain highly viable Kanslets after cryopreserving them for 4 weeks to 6 months in duration. 
CP Kanslets maintained their ability to reverse hyperglycemia in diabetic rats at a lower volume 
of transplanted tissue than fresh islets. The successful long-term cryopreservation technique 
presented here for storing pancreatic islet cells as compared to intact pancreatic islets provides 
advantages in several applications. It will not only provide additional time for quality control tests 
to be completed before islet transplantation, but also islets from different donors can be 
























People with type 2 diabetes are typically treated with a pharmacological therapy. 
However, the rate of diabetes-related complications continues to be high with diabetes as the 
leading cause of blindness, amputations and kidney failure. Finding a better pharmacological 
method to control blood glucose is key to improved outcomes. Currently, primary drug screening 
is performed on transformed β-cells, which fail to be predictive of the response in vivo. 3D 
human islets better predict the in vivo response to known diabetic drugs. However, when using 
human tissue there is great variability in the insulin response between donors, and hence the 
drug testing needs to be performed with a large number of human donors. To circumvent the 
need for assay repetition, we created multi-donor reaggregated human islets, called Kanslets. 
The purpose of this study was to determine whether drug screening with multi-donor Kanslets 
offered a superior platform for diabetes drug screening. 
Islets from different human donors were dispersed and cryopreserved as single cells and 
subsequently used to create single-donor (reaggregated cells from single-donor) or multi-donor 
Kanslets (reaggregated cells from different donors). Viability and cell composition were 
measured for single- and multi-donor Kanslets. Insulin secretion was measured after exposure 
to increasing concentrations of known diabetic drugs, which either stimulate (glucose, 
glibenclamide) or inhibit (somatostatin) insulin secretion in vivo. Islet cells reaggregated within 
3-5 days to form highly viable single- and multi-donor Kanslets. Within each cluster, the 
percentage of β-, α-, and δ- cells was not different. However, the cells within the multi-donor 
clusters were not equally comprised of cells from each donor. On average one donor comprised 
60% of the cells while the second donor comprised only 40% of the cells. However, single-donor 
as well as multi-donor Kanslets showed little responsiveness to the different drugs tested, thus 






The prevalence of diabetes has been continuously increasing. In the US, 25.8 million 
people were suffering from diabetes in 2010 but this number rose to 29.1 million in 2012 
(American Diabetes Association 2014). Type 2 diabetes accounts for 90-95% of all cases of 
diabetes (Center for Disease Control and Prevention 2011). According to a recent study, in the 
US every 2 in 5 adults are expected to suffer from type 2 diabetes throughout their lifetime 
(Gregg, Zhuo et al. 2014). 
Pharmacological therapy is the most common therapy for type 2 diabetes. For more than 
50 years, researchers have been trying to develop new drugs that would better control blood 
glucose levels in people with the disease (White 2014). Insulin and sulphonylureas have been 
the most commonly used drugs in past, but other classes of drugs like biguanides, incretins and 
thiazolidinediones are now available. Unfortunately, the new drugs, just like the older 
generations, can have severe side effects. Sulphonylureas are known to cause hypoglycemia 
(Bolen, Feldman et al. 2007, Barnett, Cradock et al. 2010). Metformin, a biguanide can cause 
gastrointestinal side effects as well as lactic acidosis (DeFronzo, Fleming et al. 2016). Drugs 
based on glucagon-like-peptide-1, which target the incretin system, have a causal relationship 
to pancreatic cancer and pancreatitis (Ryder 2013). Hence, there is a need to discover new, 
more effective drugs for diabetic patients, without the severe side effects. 
The high cost associated with bringing the new drug to clinic and the high failure rate 
associated with clinical candidates argues for an urgent need for the development of suitable 
preclinical models that can efficiently and accurately predict the efficacy in humans. Currently, 
candidate drug screening is completed on models such as transformed pancreatic β-cells that 
fail to mimic the in vivo response reliably (Hohmeier and Newgard 2004). Moreover the 
phenotypic characteristics of a cell line can change in culture over time (Efrat 1999, Borrell 




used for screening truly represents the function and physiology of primary β-cells in vivo 
(Gilligan, Jewett et al. 1989, Wang, Beattie et al. 1997, Baroni, Cavallo et al. 1999). It is 
therefore difficult to get predictive results using these two dimensional (2D) cell line models and 
there is a need for better model systems for reliable drug screening.  
It is widely believed that three dimensional (3D) cultures are far more superior to 2D 
cultures in predicting in vivo efficacy (Green and Yamada 2007, Walpita, Hasaka et al. 2012). 
While 2D culturing has been used historically to discover and test drugs, in vivo β-cells do not 
exist in a monolayer. Instead, they exist as 3D clusters together with other types of cells like α- 
and δ- cells (Li, Sun et al. 2013). Thus, it is not surprising that 3D human islets might better 
predict the in vivo response to known diabetic drugs (Gao, Wang et al. 2016).  
Rodent islets are generally used as secondary screens as well, but there are 
disadvantages to using rodent islets too. There is huge variation in the size of the rodent islets, 
varying from 40-400μm (MacGregor, Williams et al. 2006). Also, there are some physiologic 
differences between rodent and human islets including enzyme activity, and protein level 
(Olson, Betton et al. 2000). With the use of human islets in the early drug discovery phase, 
species differences can be avoided, which can help to better predict the outcomes of a drug in 
the human body. A barrier to using human islet tissue is the inability to store islets for 
convenience and the requirement of repetitions on different donor islets to get an averaged 
response due to the great variability between the drug responses of different donors. 
In this study we created multi-donor Kanslets (reaggregated islet cells from different 
donors) for the testing of reference drugs. This is the first study to create multi-donor Kanslets 
using banked human islet cells in order to minimize the need for repeated assays. This will help 
make the drug screening process more efficient in terms of time as well as money. The time and 
cost-savings to the pharmaceutical industry has the potential to successfully move more drugs 




We determined whether a mix of pancreatic islets cells from two different human donors will 
give an average dose/response to insulin secretagogues (glucose and glibenclamide), and an 
inhibitor (somatostatin). 
3.3. Methods 
Our published cryopreservation technique was used to preserve islets as single cells 
and later reaggregated to form single- (reaggregated cells from single-donor) or multi-donor 
Kanslets (reaggregated islet cells from two different donors). Results from three different trials 
were averaged, and two human donors were utilized for each trial. We compared the average 
dose response curve to insulin secretagogues (glucose and glibenclamide), and an inhibitor 
(somatostatin). We also looked at the viability and cell composition of multi-donor and single-
donor Kanslets.  
Tissue Procurement 
Native human pancreatic islets were ordered from National Institutes of Health-
Integrated Islet Distribution Program (IIDP). Pancreatic islets from human donors with diabetes 
or any other metabolic disorders were not included for the study. Characteristics of human islet 
donors used in this study are shown in Table 2 and only islets with high purity (>75%) were 
included in the study. As the islets were received, they were placed in tissue culture plates 
containing Connaught Medical Research Laboratories 1066 (CMRL; cat. no. MT5110CV; Fisher 
Scientific; Chicago, Illinois) medium supplemented with 10% fetal bovine serum (FBS; cat. no. 
26140079; Life Technologies; Chicago, Illinois), 1% antibiotic/antimycotic (cat. no. 15240062; 
Thermo Fisher Scientific; Massachusetts, USA) and 1% glutamax (cat. no. 35050061; Thermo 
Fisher Scientific). After allowing the islets to recover for 24 hours in an incubator at 37ºC and 




















Islet cell dissociation 
Islets were dispersed into single cells according to our previously published protocol 
(Williams, Wang et al. 2009). In short, islets were placed in a 50 ml tube and centrifuged at 1209 
g for 5 minutes. The islets were washed twice with calcium and magnesium-free Hank’s 
balanced salt solution (cmf-HBSS; Cat. No. SH30031.02; GE Healthcare Lifesciences; South 
Logan, Utah). Subsequently, the digestion medium consisting of cmf-HBSS and papain (5 
units/ml; Worthington, Lakewood, NJ) in ratio of 3:1 was added to the islets. The suspension 
was incubated on a rotor at 37ºC for a maximum of 20 minutes. Islets were then dispersed 
using a pipette. Digestion was stopped using culture medium containing calcium and 
magnesium. The cells were washed twice at 1209 g for 5 minutes to remove the papain.  
Cryopreservation of single islet cells 
Dissociated single cells were cryopreserved according to our patent pending protocol 
described in our previous study (Rawal, Harrington et al. 2016). In short, single cells were 
centrifuged to form a pellet and the supernatant was removed. Cells were placed in 1 ml of 
CryoStor CS10 (cat. no. C2874; Sigma Aldrich, St. Louis, Missouri) and kept in a cool cell (cat. 
no. BCS-405; Biocision; San Rafael, CA), which freezes the sample at 1ºC/minute. Samples 




performed to release the latent heat of fusion by mechanical agitation and samples were moved 
back to -80ºC. Samples were stored in liquid nitrogen at -196ºC. For the preliminary trial, donor 
1 and 2 were CP for 7-10 days whereas for the next two trials islet cells were CP for 5-7 
months. At the time of thawing, cells were incubated in a water bath at 37ºC until the last ice 
crystals melted. They were diluted with the fresh culture media containing CMRL supplemented 
with 10% FBS, 1% l glutamine and 1% antibiotic and antimycotic.  
Seeding the cells into micromold 
Single cells were seeded into the micromold as described in our previously published 
protocol (Ramachandran, Williams et al. 2013). In short, cells in 3 ml of culture media consisting 
of CMRL supplemented with 10% FBS and 1% antibiotic and antimycotic were carefully plated 
into the micromold. The micromold was incubated at 37ºC and 5% CO2. Cells reaggregated and 
formed Kanslets within 3-5 days. The culture media was changed every 24 hours. After the 
Kanslets were formed they were removed from the mold by washing several times with the 
culture medium and moved to a petri dish. 
Viability 
Cell death was analyzed using Yo Pro 1 and propidium iodide staining. Images were 
captured under an Olympus FluoView 300 confocal microscope, and analyzed using abode 
Photoshop CS 5 Extended. The total islet pixel number as well as the positively stained pixels 
were used to calculate the proportion of live as well as dead (apoptotic and necrotic) cells.  
Immunofluorescence staining of α-, β- and δ-cells 
In order to analyze the proportion of α-, and δ- cells, single-donor and multi-donor 
Kanslets were stained for insulin (β-), glucagon (α-) and somatostatin (δ-) cells as described in 
our previously published protocol. Briefly, permeabilization of the cells was completed in 1% 




two hours at room temperature with primary antibodies against insulin (1:100, cat. no. ab7842; 
Abcam, Cam bridge, MA), glucagon (1:300, cat. no. ab10988; Abcam) and, somatostatin (1:300, 
cat. no. ab53165; Abcam). After incubating with the primary antibody, single- and multi-donor 
Kanslets were washed with PBS three times for five minutes each, and incubated in a mix of 
fluorophore conjugated secondary antibodies consisting of DyLight 488 (1:400, cat. no. 706-
485-148; Jackson ImmunoResearch Laboratories Inc., West Grove,), Alexa 555 (1:400, cat. no. 
A31570; Thermo Fisher Scientific) and Alexa 647 (1:400, cat. no. A31573; Thermo Fisher 
Scientific) in a dark wet chamber for one hour. After incubation with secondary antibodies, 
Kanslets were washed in PBS three times for five minutes and mounted on microscopic slides 
with anti-fading agent Gel/Mount (Biomeda, Foster City, CA). The following solution was used to 
dilute primary and secondary antibodies: 1% BSA, 0.03% Triton X-100 and PBS. Images were 
captured on a Nikon C1Si or C1 Plus confocal microscopes. For each group, 20-25 islets were 
analyzed for the cell composition. For cell composition analysis, the relative proportion of α-, β-, 
or δ-cells in each islet was evaluated by counting the number of individual types of cell and 
dividing it by the total sum of endocrine (α-, β-, and δ-) cells per islet. Image J was utilized to 
perform cell composition.  
Proportion of cells from different donors in the multi-donor Kanslets 
Before mixing islet cells from two different donors to create multi-donor Kanslets, cells 
from different donors were labelled with unique markers; carboxyfluorescein diacetate, 
succinimidyl ester (CFDA-SE) and DiI according to the manufacturer’s instructions. In short, 
after centrifugation and aspirating the supernatant, the islet cell pellet was re-suspended in a 
pre-warmed (37ºC) PBS containing 10µm of CFDA-SE. Afterwards cells were incubated for 15 
minutes at 37ºC and then centrifuged. The supernatant was removed and cells were washed 
twice and re-suspended in pre-warmed fresh medium containing CMRL, 10% FBS, 1% 




pancreatic islet cells with DiI, cells were resuspended in 1 ml of serum free culture media. 5µl of 
DiI at a working concentration of 5mM was added to the tube and mixed gently using a pipette 
and incubated for 15 minutes at 37ºC. Cells were centrifuged at 1209 g for 5 minutes and re-
suspended in fresh medium. Cells were washed again twice and re-suspended in fresh medium.  
After labeling, the islet cells from the different donors were mixed thoroughly in equal 
proportions and were seeded into the micromold to allow them to reaggregate. After 
reaggregation, Kanslets were removed from the micromold by washing the mold and aspirating 
Kanslets using a pipette. After allowing the hybrid clusters to recover in fresh culture medium, 
Kanslets were seeded on microscopic slides and mounted with anti-fading agent Gel/Mount 
(Biomeda, Foster City, CA. Images were captured using the Nikon C1Si or C1 Plus confocal 
microscope. Images were analyzed using Image J to determine the percentage of islet cells 
from either donor in the multi-donor Kanslets.  
Response to insulin secretagogues and inhibitors 
We compared 7 half-log dose response curves to insulin secretagogues (glibenclamide) 
and an insulin inhibitor (somatostatin). Stock solutions for glibenclamide (10µM), and 
somatostatin (300nM) were made in dimethyl sulfoxide (DMSO) and water respectively. For 
static incubation, single- or multi-donor Kanslets were handpicked with a micropipette and a 
known quantity of islet equivalents (IEQs) were distributed in 96 well plates containing 200 µl of 
Earle’s balanced salt solution (EBSS), 11.2mM of glucose and corresponding drug. Each dose 
was tested in repetitions of six. After 60 min of static incubation at 37ºC and 5% CO2, 
conditioned medium was collected and frozen at -80ºC. The insulin concentration was later 
quantified using a human ELISA kit (cat. no. 80-INSHU-E01; ALPCO; Salem, NH) per the 
manufacturer’s instructions. In short, standards and samples were added to the insulin specific 
monoclonal antibody coated microplate wells. After incubating the samples and standards with 




microplates were subsequently incubated for 15 minutes after adding the substrate. The optical 
density was measured at 450nm by a spectrophotometer after adding the stop solution. Optical 
density values were divided by the respective number of IEQ’s in each well for normalization.  
Data Analysis  
Sigma plot was used for data analysis. To determine between group differences for cell 
composition and viability, a t- test was performed. To determine equivalence between groups 
(average of all single-donor Kanslets and multi-donor Kanslets) for dose response curve to 
insulin secretagogues, and inhibitor, we used the bioequivalence statistical test. Anything 25% 
above or 20% below the bound (difference between the mean of two groups) was considered a 
significant difference (http://www.fda.gov/drugs/developmentapprovalprocess/ucm079068.htm 
2012, Li 2012). An alpha level of 0.05 was utilized to determine the significance of these 
findings. Results of all experiments were expressed as the average ± SE. 
3.4. Results 
Proportion of cells from different donors in multi-donor Kanslets 
Islet cells from a donor were stained with CFDA-SE while cells from another donor were 
stained with DiI during each repetition. Representative images of single-donor Kanslets stained 
with CFDA-SE (green) or DiI (red) along with a multi-donor (containing cells from both donors) is 
shown in Figure 14A. As evident in the image, multi-donor Kanslets contained cells from both 
donors. However, the proportion of cells from each donor was not equal in the Kanslets, even 











Figure 14. Co-localization of islet cells from different donors in multi-donor Kanslets.  
A) In each trial cells from one donor were stained with CFDA-SE (green) and reaggregated 
into Kanslets. Cells from another donor were stained with DiI (red). Additionally, cells from 
the two different donors were mixed prior to reaggregation and the resulting multi-donor 
Kanslets show with cells from two different donors. Scale bar=100µm. B) The proportion of 
islet cells from different donors in the multi-donor Kanslets indicates that the multi-donor 
Kanslets did not contain an equal proportion of cells from both donors. Approximately, 50-




Proportion of α-, β- and δ-cells 
The percentage of the different endocrine cells within the Kanslets was compared for the 
single- and multi-donor Kanslets. There was no significant difference in the proportion of β-cells 
between the single-donor and the multi-donor Kanslets. β-cells were the predominant cell type, 
comprising 60-65% of the cells, in all of the formed aggregates (Figure 15). By contrast, there 
was a difference in the percentage of α-cells between the two groups with the single-donor 
Kanslets comprising statistically more α-cells (Davalli, Ogawa et al.) compared to the multi-
donor group (27%). Likewise, there was a significant difference in the proportion of δ-cells in 
both the groups with δ-cells constituting the third dominant cell type in both single-donor (4%) 




Figure 15. Islet cell composition of single-donor and multi-donor Kanslets.  
There was no significant difference in the islet cell composition of beta cells between 
single- and multi-donor Kanslets but there was significant difference between the α-and 
delta cells in both the groups. All the values are expressed as average ± SE. 45-50 









The viability of single- and multi-donor Kanslets from all the trials was assessed by Yo 
Pro 1 and propidium iodide staining, which measures cell death through apoptosis and necrosis. 
Figure 16 shows the percentage of viable and dead cells in the single- and multi-donor groups. 
Due to the low level of variance, there was significant difference in the proportion of viable and 
dead (apoptotic and necrotic) cells between the two groups with the multi-donor Kanslets 
showing a slightly better viability. However, both groups had excellent viability that was greater 




Figure 16. Percentage of viable and dead cells (apoptotic and necrotic) in 
single- and multi-donor Kanslets.  
There was significant difference in the percentage of viable and dead cells at 24 
hours between single- and multi-donor Kanslets created by using islet cells from 





Response to insulin secretagogues and inhibitors 
Glucose:  
β-cells in the pancreatic islets function by releasing insulin in response to glucose 
stimulation (Haist 1971). We exposed single-donor as well as multi-donor Kanslets to increasing 
glucose concentrations and measured the amount of insulin secreted. Single-donor Kanslets 
from donor 1 and donor 2 as well the multi-donor Kanslets were challenged with different 
concentrations of glucose and secreted insulin was measured. Donor 1 had a peak insulin 
secretion level when exposed to 11.2mM glucose, which was 2 times greater than the basal 
insulin secretion at 1.4mM glucose (Figure 17). Donor 2 was unresponsive to different glucose 
challenges, illustrating the challenge of working with human donor tissues for drug screening. 
The glucose sensitivity of the multi-donor Kanslets, composed of cells from these 
donors, fell between the individual donors’ responses. A bioequivalence test of the preliminary 
data for the glucose dose response curve for multi-donor Kanslets and mathematical average of 
the two single-donor Kanslets suggested that the multi-donor Kanslets were bioequivalent to the 
averaged single-donor responses. This preliminary experiment supported the hypothesis that 









Figure 17. Glucose stimulated insulin secretion of two single-donor (donor 1, donor 2) 
and multi-donor Kanslets (equal proportion of cells from donor 1 and donor 2).  
The response of multi-donor Kanslets was approximately in the middle of the two single-donor 
Kanslets. Two single-donor Kanslets and multi-donor Kanslets had peak responses at 
11.2mM glucose concentration. All values are expressed as average ± SE, 4 replicates for 




The results of repetitions of this experiment are summarized with the EC50 (effective 
concentration to elicit a 50% response), and the peak effect of single- as well as multi-donor 
Kanslets (Table 3). Both groups of Kanslets showed blunted increases in insulin secretion with 
exposure to higher glucose concentrations. This is demonstrated by the peak effect, which is 
the difference in the lowest insulin secretion value compared to the maximum insulin response. 
Compared to the responsive cells shown in Figure 17, which had a peak effect of 163 ng/ml, the 
subsequent trials elicited responses that were less than half as strong. The EC50 values 
indicated that the single-donor Kanslets were more responsive to lower concentrations of 
glucose than the multi-donor group.  
Glibenclamide:  
Glibenclamide acts by enhancing insulin secretion by binding to the SUR subunit of ATP 
sensitive potassium channel and thereby causing its closure and opening of calcium channel 
(Luzi and Pozza 1997, Proks, Reimann et al. 2002). In single- and multi-donor Kanslets, we 
again noted a blunted increase in insulin secretion when the glibenclamide concentration was 
increased. The EC50 of the multi-donor Kanslets was dramatically less than the single-donor 
group, which normally would point to a more potent assay. However, the peak effects for the 
multi-donor group was quite small and so no conclusions could be drawn. 
Somatostatin:  
Somatostatin inhibits the insulin secretion by activation of somatostatin receptors 1 and 
5 (Schwetz, Ustione et al. 2013). When single- and multi-donor Kanslets were tested for 
somatostatin, yet again with increasing drug concentrations, an expected response towards 
decreasing insulin secretion was not seen. Single-donor Kanslets had a calculated theoretical 




drawn. The multi-donor group had a reasonable EC50, but a very small peak effect, again 
leading to the inability to draw conclusions based on the results. 
 






















149.03 ± 43.28 102.66 ± 25.88 41.97 ± 11.63 
Single- and multi-donor Kanslets were exposed to increasing concentrations of insulin 
scretagogues (glucose, glibenclamide) and an inhibitor (somatostatin). The EC50 was 
calculated based on the average insulin secretion response of all the trials after exposing the 
single-donor and multi-donor Kanslets to different drugs and their increasing concentrations. 
SigmaPlot was utilized to calculate the EC50 values. Single donor Kanslets (glucose: n=6, 
glibenclamide and somatostatin: n=4); multi-donor Kanslets (glucose: n=3, glibenclamide and 






Currently, drug testing is performed on 2D cultures, which fail to mimic how the drug 
would respond in vivo. Previously, we have shown that Kanslets created from fresh human islet 
cells are more sensitive to different drugs, and their increasing concentrations than native 
human or rat islets (Ramachandran, Peng et al. 2014). In order to minimize the need for 
repetitious performance of candidate drug screening on β-cells from a large number of different 
human donors, we created multi-donor Kanslets, consisting of islet cells from different donors. 
We anticipated that the multi-donor Kanslets would give an average drug response of different 
single-donor Kanslets used to create the multi-donor spheroids in the study. We were 
successful in creating the multi-donor Kanslets, which were highly viable. The cell composition, 
comprised of α-, δ-, and β-cells, was similar to the cell composition of single-donor Kanslets and 
to the values reported for fresh native islets (Brissova, Fowler et al. 2005, Steiner, Kim et al. 
2010). In the first trial, one donor responded to increasing glucose concentrations, while cells 
from the second donor failed to respond with an increase in insulin secretion. The mathematical 
average of the two curves was bioequivalent to the measured values from the multi-donor 
Kanslets. In the two subsequent trials with islet cells from four different donors, the Kanslets 
were responsive to glucose, but the peak effect was quite small, compared to donor 1. 
Interestingly, the single-donor Kanslets were more responsive than multi-donor with a lower 
EC50 and a larger peak effect. All Kanslets groups failed to respond to a stimulant drug, 
glibenclamide, or an inhibitor, somatostatin. 
The most likely explanation for the poor responsiveness of the Kanslets tested in this 
study was the storage conditions.  It is difficult to create multi-donor Kanslets using fresh human 
islet cells, as it is unlikely for a site to receive pancreatic islets from two or more human donors 
at the same time. Thus, the islet cells used in this study were cryopreserved using the optimized 




cryopreserved them as single islet cells until we had another donor isolated. We have previously 
shown that Kanslets created using cryopreserved human islet cells are highly viable and 
diabetic rats returned to normoglycemia when transplanted with cryopreserved Kanslets (Rawal, 
Harrington et al. 2016). In our previous study, islet cells were typically cryopreserved for less 
than 4 months. In order to collect enough cells from qualified donors for this study, islet cells 
from all the donors were cryopreserved for 5-7 months. We have previously seen that islet cell 
death increases with the length of cryopreservation (Rawal, Harrington et al. 2016). All these 
observations suggest that duration of cryopreservation in this study may have adversely 
affected the outcome after thawing. 
An additional explanation for the results revolves around the quality of the donor tissue. 
As described in table 1, we tried to exclude donors whose physical condition might adversely 
affect islet health, such as diabetes or other metabolic disorders. However, many human donors 
are overweight and we could not exclude all of them. Unfortunately, the islets used in the study 
were all from donors who were either overweight or obese. Long term exposure to fatty acids 
can lead to fat deposit within the islets and also exposure to fatty acids can lead to loss of co-
localization of calcium channels and secretory granules which could have also made islets 
secrete less insulin (Hoppa, Collins et al. 2009, Ashcroft and Rorsman 2012). 
Finally, the handling of the islets after removal from the donor could negatively affect the 
tissue quality. Cold ischemia time is that amount of time beginning with the chilling of the tissue 
after removal from the body to the warming of the pancreas to start the digestion process for 
removing the islets from the exocrine tissue. The average cold ischemia time for our donor 
tissue was 11-20 hours (Table 2), which is considered a longer duration. Previous studies have 
noted that cold ischemia times of greater than 8 hours lead to reduced quality of human islets 
(Hanley, Paraskevas et al. 2008). Thus the long cryopreservation and the quality of the donor 




One of the most interesting findings of the study was the unequal distribution of cells from 
different donors. In each matched pair, islets from one donor appeared to outnumber the cells 
from the other donor by a ratio of 60 to 40%. However, on further review, the cells stained with 
DiI were always more prevalent than the cells stained with CFDA-SE. This leads one to the 
explanation of an artifact. In our experiments, DiI stain diffused to the neighboring cells staining 
the whole multi-donor Kanslet. In order to take this into consideration, cells that appeared to be 
double-labeled with CFDA-SE and Dil were counted as CFDA-SE only. However, there could 
have been cases where enough DiI was transported into CFDA-SE-positive cells that it 
overwhelmed the green fluorescence and the cells were misidentified as DiI-positive. 
Improvements in the study would include; reduced cryopreservation time, more stringent 
donor criteria (including cold ischemic time), and different fluorophores used in the donor-
specific staining. However, many of these improvements would also make the study extremely 
costly, if not impossible. With the current protocol, we had difficulty obtaining sufficient quantities 
of islets to be able to make single- and multi-donor Kanslets from the same donors. Thus, 
creating more stringent donor criteria would have exacerbated the problem. In addition, we, the 
end-user, have no control over the cold ischemia time at the donor site. Thus, requiring a 
shorter ischemic time would also have drastically limited the number of donors. 
3.6. Conclusion  
In conclusion, the concept of multi-donor assays to reduce the time and cost of drug 
screening is appropriate in many situations. For example, in cancer drug screening where tumor 
cells are removed from patients and transformed into cell lines, because of the inherent 
characteristic of cancer cells to grow and divide, multi-donor tumors work well for candidate 
screens. Islet cells are more challenging, because they rarely proliferate in vivo in adult humans 


















Integration of Mesenchymal Stem Cells and Islet Cells into Spheroids 





Pancreatic islets, especially the large islets (>150µm in diameter) have poor survival 
rates in culture. Co-culturing with mesenchymal stem cells (MSCs) has been shown to improve 
islet survival and function, especially when the different cell types are in close contact, defined 
as islets cultured in media containing MSCs. The purpose of this study was to determine 
whether islet survival and function was improved, when the two populations of cells were 
intermingled with each other in a defined geometry. Hybrid spheroids containing 50% or 75% 
islets cells with appropriate number of MSCs were created along with spheroids comprised of 
only islet cells or only MSCs. All the groups were tested for the number of spheroids, proportion 
of spheroid type, proportion of islet cells and MSCs, viability, diameter, glucose stimulated 
insulin secretion (GSIS) and glucose stimulation index (SI). Spheroids were formed within 3-5 
days. All the groups were highly viable with average diameters under 80µm at formation. Both 
the hybrid spheroid groups preferred to cluster in islet-only spheroids. Over a 2 week period, 
spheroids in all the groups significantly increased in their diameter but not their number. SI 
(calculated as insulin secretion/ islet cell at high glucose challenge to insulin secretion/ islet cell 
at low glucose exposure) was significantly less in the 75% islet cell (1.3±0.8) compared to 
spheroids containing only islet cells (4.1±0.7) at day 1 whereas there was no significant 
difference in the SI of 50% islet cell group (1.7±0.8) compared to the spheroids containing only 
islet cells. Our study showed that it was possible to create highly viable hybrid spheroids 
consisting of MSCs and islet cells intermingled, and in direct contact with each other, but this 






Islets of Langerhans, containing the insulin-producing cells of the body, are multicellular 
clusters of endocrine cells found in the pancreas that vary in size from 20 µm to more than 400 
µm in diameter (Huang, Novikova et al. 2011). Pancreatic islets in the human body have a rich 
blood supply from a dense capillary network (Zanone, Favaro et al. 2008), which is ten times 
higher than that of the surrounding exocrine tissue. However, when these islets are isolated, the 
clustered cells must survive solely on diffusion (Carlsson, Liss et al. 1998, Williams, Huang et al. 
2010). 
Traditional cell culture approaches for islets often yield poor results with cells generally 
dying after 7 days in culture (Chun, Huang et al. 2008). In large size islets (> 150µm) core cell 
death has been measured within 24 hours in culture (Li, Zhao et al. 2014). For decades 
researchers have attempted to improve the culture conditions for isolated islets, with little 
improvement in long-term culture outcomes. Further, the clinical islet transplantation procedure 
requires extended periods of islet culture prior to transplantation while quality assurance assays 
are conducted on the donor islets (Andersson, Borg et al. 1976). Thus, it is important to 
maintain the islets in culture so that they can be utilized effectively for research purposes or islet 
transplantation. 
Co-culture is a popular procedure in which different populations of cells are cultured 
together either to investigate the cellular interaction between different cell types or to help 
improve the cultural conditions (Goers, Freemont et al. 2014). It has been known for decades 
that certain cell types are difficult to maintain in a monoculture, but do better in a co-culture 
environment (Xu, Roberts et al. 1982, Harcombe 2010, Wu, Huang et al. 2010, Park, Kerner et 
al. 2011, Hesselman, Odoni et al. 2012). Cultured islets are already a co-culture, as there are at 
least 4 primary endocrine cell types, and a number of supporting cells in each islet.  Loss of 




reduced efficiency of islets in culture (Wang and Rosenberg 1999, Nyqvist, Kohler et al. 2005, 
Kin, Senior et al. 2008). Recently, the concept of adding extra support cells to the pancreatic 
islet culture has been investigated with a number of different cell types including hepatocytes 
and mesenchymal stem cells (MSCs) (Verga Falzacappa, Mangialardo et al. 2010). The goal of 
the new approaches has been to improve islet cell function, and long-term viability by mixing 
additional cells into the culture media. 
MSCs are a reasonable option for supporting islet health. MSCs can be derived from 
various different adult tissues like bone marrow, adipose or peripheral blood.(Brunt, Hall et al. 
2007, Hass, Kasper et al. 2011) MSCs have the ability to self-renew and self-proliferate (Via, 
Frizziero et al. 2012). MSCs help with repair and regeneration of tissues of different origins like 
neuronal (Park, Lee et al. 2008), cardiac (Takahashi, Li et al. 2006) and skeletal (Lee, Seo et al. 
2006, Wu, Chen et al. 2007). Release of anti-apoptotic (Xu, Zhang et al. 2007), anti-
inflammatory (Iyer and Rojas 2008), anti-oxidant (Ayatollahi, Hesami et al. 2014), 
immunosuppressive (Aggarwal and Pittenger 2005, Uccelli, Moretta et al. 2008) and angiogenic 
(Tang, Zhao et al. 2004, Zacharek, Chen et al. 2007, Ito, Itakura et al. 2010) factors by stem 
cells has been shown to help with tissue repair and regeneration. Further, MSCs may be 
protective to islet cells, because when pancreatic islets were co-cultured with MSCs, their 
survival and function improved (Chao, Chao et al. 2008, Boumaza, Srinivasan et al. 2009, Park, 
Kim et al. 2009, Karaoz, Genc et al. 2010, Lu, Jin et al. 2010, Scuteri, Donzelli et al. 2014). 
Many techniques have been attempted to successfully co-culture islets with MSCs. 
Transwell plates, 3D scaffolds, and microfluidic platforms have been used for co-culturing. In 
indirect co-culture, islets are separated from MSCs by a semi-permeable membrane or an insert 
(Rackham, Dhadda et al. 2013). In direct co-culture, islets are allowed to contact the MSCs, 
either attached to a plate or in suspension. A few studies have reported that direct co-culture is 




2011). Direct contact with MSCs appears to help islets maintain their structural integrity (Luo, 
Badiavas et al. 2007). Yet, even with direct contact, the islet cells remain in a separate spheroid, 
typically with MSCs attached to the outer layer (Jung, Kim et al. 2011). The goal of this study 
was to determine if intermingling MSCs with islet cells in the same spheroid would further 
improve islet cell survival and function. 
Hybrid islet and MSC spheroids of small uniform sizes were created. In order to know 
the right ratio of MSCs and islet cells needed to form viable and functional hybrid spheroids, we 
created hybrid spheroids consisting of different proportions of islet cells and MSCs. In this study, 
we aimed to look at the number of spheroids formed, viability (days 1 and 14), morphology and 
stimulation index of these hybrids containing different proportion of MSCs and islet cells. 
4.3. Methods 
Isolation of rat pancreatic islets 
Pancreatic islets were isolated and dispersed according to our published protocol 
(MacGregor, Williams et al. 2006, Williams, Wang et al. 2009, Williams, Huang et al. 2010). The 
protocol for isolation of rat pancreatic islets was approved by Institutional Animal Care and Use 
Committee at University of Kansas Medical Center. In brief, 32 Sprague Dawley rats (Harlan; 
Indianapolis, Indiana) were anesthetized by intraperitoneal injection of ketamine and xylazine. 
After opening the peritoneal cavity, the pancreatic main duct to the duodenum was clamped and 
distended with cold collagenase (CLS1, 450 units/mL; Cat. No. LS004197 Worthington; 
Lakewood, NJ). The pancreata were excised and incubated with gentle rotation for 20–30 min in 
a 37ºC incubator. After washing and straining the contents of the tube through a 500µm mesh 
screen, the pellet was mixed with 3:1 mixture of histopaque 1077 and 1119 (density = 1.1085; 
Cat. No. 11191 and 10771; Sigma Aldrich; St. Louis, Missouri) and centrifuged beneath the 




Healthcare Lifesciences; South Logan, Utah).The islets, collected from the gradient, were 
sedimented and washed with Hank’s Balanced Salt Solution (HBSS, Cat. No. SH30030.02; GE 
Healthcare Lifesciences) supplemented with 5% BCS over a sterile 40-mm mesh cell strainer. 
Islets were placed into Connaught Medical Research Laboratories (CMRL; Cat. No. MT5110CV; 
Fisher Scientific; Chicago, Illinois) medium supplemented with 10% FBS, 1% 
antibiotic/antimycotic (Cat. No. 15240062; Thermo Fisher Scientific; Massachusetts, USA), and 
1% glutamax (Cat. No. 35050061; Thermo Fisher Scientific) and allowed to recover for 24 hours 
in an incubator at 37ºC and 5% CO2. 
Dispersing islets into single cells 
Native rat islets were dispersed into single cells according to our previously published 
protocol (Ramachandran, Williams et al. 2013). In short, islets were collected in 50 ml tubes and 
centrifuged. Then the islets were washed twice with calcium and magnesium free (cmf) HBBS 
(Cat. No. SH30031.02; GE Healthcare Lifescienc. After that, the digestion medium, consisting of 
cmf-HBSS supplemented and papain (3 units/ml; Cat. No. 9001-73-4; Worthington), was added 
to the islets and the suspension was incubated on a rotator at 37ºC for a maximum of 20 
minutes. Islets were further dispersed using a pipette until the media primarily contained single 
cells. Digestion was stopped using CMRL medium containing calcium and magnesium. The 
cells were subsequently washed to remove the papain. Cells were brought up in CMRL medium 
containing 10% FBS, 1% antibiotic/ antimycotic and 1% glutamax before mixing them with 
MSCs in appropriate proportion. Hemocytometer counts were performed to determine the 
number of islet cells. 
Establishing and passaging MSCs 
Bone marrow MSCs from Sprague Dawley rats (Cat No. RASMX-01001; Cyagen 




In brief, the cryovial containing MSCs was quickly thawed at 37ºC in a water bath. Cells were 
transferred to a 50 ml centrifuge tube containing MSC medium supplemented with 10% FBS, 
1% penicillin/ streptomycin and 1% glutamine (Cat. No. GUXMX-90011; Cyagen Biosciences 
Inc.). After centrifugation, the pellet of cells re-suspended in the fresh MSC medium 
supplemented with 10% FBS, 1% penicillin/ streptomycin and 1% glutamine, were seeded into a 
T25 flask and incubated at 37ºC and 5% CO2. The medium was changed every 2-3 days and 
cells were trypsinized when they were 80-90% confluent. Adherent MSCs cells were detached 
with trypsin-ethylenediaminetetraacetic acid (trypsin- EDTA; 0.05% trypsin-EDTA in cmf-HBSS; 
Cat. No. 15400054; Thermo Fisher Scientific) solution for 5-10 minutes at 37ºC and 5% CO2. 
Trypsin-EDTA was neutralized by addition of culture medium containing calcium and 
magnesium. The cell suspension was centrifuged at 435 g for 5 minutes. The supernatant was 
removed and the pellet was distributed in 75 cm2 flasks with the MSC medium supplemented 
with 10% FBS, 1% antibiotic/ antimycotic and 1% glutamine. After the cells reached 70-80% 
confluency, they were passaged again and cells were reseeded. Once the appropriate number 
of cells was obtained, MSCs were trypsinized and dispersed in MSC growth media before 
mixing them with islet cells in defined proportions. 
Seeding the cells in the micromold to form hybrid spheroids 
After performing the cell count for islet cells and MSCs using hemocytometer, single 
cells were mixed in appropriate proportions and seeded into a micromold, as described in our 
previously published protocol (Ramachandran, Williams et al. 2013). The cells were plated in 
the micromold with 3ml of culture media, incubated at 37ºC and 5% CO2. Cells reaggregated 
and formed hybrid spheroids within 3-5 days, with daily media changes. Subsequently, they 
were removed from the mold by washing multiple times with the culture medium. Table 4 
describes the groups and the proportions of islet cells and MSCs loaded in each spheroid 




few spheroids were created to be able to conduct tests with confidence. Thus, only data from 




Table 4. Proportion of islet cells and MSCs loaded in each group. 
Groups Proportion of islet cells Proportion of MSCs 
0% 0 100 
50% 50 50 
75% 75 25 
100% 100 0 
Groups were named according to the proportion of islet cells loaded in each group. The 50% 
and 75% groups had both cell types. The 0% group had only MSCs and no islet cells, whereas 
the 100% group had only islet cells and no MSCs 
 
Viability assessment using Yo-Pro-1 and propidium iodide staining 
Cell death was determined by double-labeling cells with Yo-Pro-1 and propidium iodide 
nucleic acid stains (Cat. No. V13243; Thermo Fisher Scientific). Yo-Pro-1 stain selectively 
passes through the plasma membranes of apoptotic cells and labels them with green 
fluorescence. Necrotic cells stained red-fluorescent with propidium iodide (Gawlitta, Oomens et 
al. 2004). 1µl of Yo-Pro-1 and propidium iodide stain each was added to 200µl of culture media 
containing spheroids from different groups. Images were taken using an Olympus Fluo View 
300 confocal microscope, later the images were analyzed using Abode Photoshop CS 5 
extended. 30-150 images were analyzed per group. Total pixels, as well as the red and green 
pixels were calculated. The percentages of necrotic and apoptotic cells was calculated by 
dividing the pixels for red/ green staining to the total pixels and multiplying by 100. The 
proportion of dead cells was assessed on day 1 after the spheroids were formed and at day 14 




Glucose stimulated insulin secretion (GSIS) 
For static incubation, spheroids were distributed in 96 well plates containing 100 µl of 
Earle's balanced salt solution (EBSS) with 2.8mM glucose. Spheroids from different groups 
were exposed to glucose concentrations of 2.8mM (low) 16.8mM (medium), 22.4mM (high) and 
22.4mM + 60mM KCl (high glucose along with depolarization at high potassium levels) for an 
hour in replicates of 6. After 60 min of static incubation at 37ºC and 5% CO2, conditioned media 
samples were collected and frozen at -80ºC. The insulin concentration was later quantified 
using a rat insulin enzyme linked immunosorbant assay kit (ELISA; Cat No. 80-INSRTH-E01; 
Alpco; Salem, NH) as per the manufacturer’s instructions. In short, standards and samples were 
added to the insulin specific monoclonal antibody coated microplate wells. After incubating the 
samples and standards with the detection antibody for two hours, the plate was washed with 
buffer. The microplate was again incubated for 15 minutes after adding the substrate. Optical 
density was measured at 450nm by a spectrophotometer after adding the stop solution. Optical 
density values were normalized by the number of spheroids as well as number of islet cells for 
each group. Glucose stimulation index (SI) was also calculated and was defined as insulin 
secretion per islet cells at 22.4mM glucose to insulin secretion at 2.4mM glucose challenge. 
Morphology of hybrid spheroids 
In order to track the interspersion of the islet and MSC in the spheroids, the different cell 
types were labelled with distinct markers. Cells from pancreatic islets were labelled with DiI (1, 
1′-dioctadecyl-3, 3, 3′, 3′-tetramethylindocarbocyanine perchlorate; Cat No. 42364, Sigma- 
Aldrich) and MSCs were labelled with CFDA-SE (carboxyfluorescein diacetate, succinimidyl 
ester; Cat. No. V12883; Thermo Fisher Scientific) according to the manufacturer’s instructions. 
In short, after centrifugation and aspiration of the supernatant, the MSC pellet was re-
suspended in a pre-warmed (37ºC) phosphate buffered saline containing 10µM of CFDA-SE. 




5 minutes, and cells were re-suspended in pre-warmed fresh MSC medium with 10% FBS, 1% 
penicillin/ streptomycin and 1% glutamine for 30 minutes, pelleted and re-suspended in MSC 
medium with 10% FBS, 1% penicillin/ streptomycin and 1% glutamine. DiI is a lipophilic 
membrane stain that diffuses laterally to stain the entire cell. In order to stain the pancreatic islet 
cells with DiI, cells were re-suspended in 1 ml of serum free culture media with 5mM DiI and 
incubated for 15 minutes at 37ºC. Cells were then centrifuged at 1209 g for 5 minutes and re-
suspended in CMRL supplemented with 10% FBS, 1% antibiotic/ antimycotic and 1% glutamax. 
After labeling, the islet cells and MSCs were mixed thoroughly in different proportions 
and were seeded into the micromold to allow them to reaggregate and form hybrid spheroids as 
described previously. Upon removal from the mold, the spheroids were placed on the 
microscopic slides (Cat. No. 12-550-12; Fisher Scientific) and mounted with anti-fading agent 
Gel/Mount (Biomeda, Foster City, California). Images were captured using a Nikon C1Si or C1 
Plus confocal microscope. Interspersion data could only be obtained from spheroids less than 4 
days after formation, because the fluorophores are depleted after that time. Images were 
analyzed using Image J to determine the percentage of islet cells and MSCs in each hybrid 
spheroid. In addition, analysis was also done to determine how many spheroids were comprised 
of a combination of islet cells and MSCs and how many consisted only of MSCs or islet cells 
alone. 
The diameter of each spheroid was measured using Adobe Photoshop CS 5. Light 
microscopic images were utilized to analyze diameter. Two perpendicular diameter 
measurements were recorded and averaged for each spheroid.  350- 2000 spheroids were 






SigmaPlot software was utilized for data analysis. To determine significant differences 
between groups for the number of spheroids, proportion of spheroid type, proportion of islet 
cells and MSCs, viability, diameter GSIS and SI, one way ANOVA was performed. To determine 
the significant within group differences at day 1 and day 14 for number of spheroids, viability, 
diameter and SI, t test was performed. An alpha level of 0.05 was utilized to determine the 
significance of these findings. 
4.4. Results 
Yield 
Spheroids were formed within 3-5 days of co-culturing of MSCs and islet cells in the 
micromold. While approximately the same number of cells was loaded into the molds to form 
spheroids in each group, the ability of the different cell mixtures to self-aggregate varied widely 
between the hybrid spheroid groups. The number of spheroids formed at day 1 for the 50% islet 
cell group was approximately 500, which was nearly 3 times less than the mixtures that had 
75% islet cells (Figure 18). Further, another group with 25% islet cells was attempted, but 
formed too few spheroids for subsequent studies (results not shown). There was no significant 
difference in the number of spheroids formed in groups 0%, 75% and 100% at day 1. The 0% 
group (all MSCs) could form clusters in low adhesive petri dishes even without the molds. The 
number of spheroids present in the 100% islet cell group dropped dramatically over the course 
of 2 weeks (Figure 1B). In contrast, all groups that contained MSCs (groups 0, 50, and 75%), 







Figure 18. Group differences in spheroid formation and maintenance. 
The total number of clusters in each group on day 1 and 14. There were more spheroids 
formed as the proportion of islet cells increased in the hybrid spheroid groups. There was no 
significant change in the number of spheroids within groups at day 14 except for the 100% 





An image of a representative spheroid from each group is shown in Figure 19A. As 
evident in the images, more islet cell staining (red) was present as the ratio of islet cells to 
MSCs increased from the 0% group to 50%, 75% and 100%. Within the hybrid groups, the 
MSCs and islet cells were either randomly distributed as shown in the example for the 75% 
group or collected together in regions found within the spheroids as shown in the 50% group 
example. These differences in cell organization appeared randomly. 
Although cells in the hybrid groups were thoroughly mixed in given proportions prior to 
loading in the micromolds, some spheroids contained only MSCs or islet cells. The percentages 
of spheroids consisting of a hybrid of islet cells and MSCs versus islet cells or MSCs alone were 
calculated (Figure 19B). There was no significant difference in the percentages of spheroids 
consisting of only islet cells, only MSCs or both between the 50% and 75% hybrid groups even 
though different proportions of islet cells and MSCs were loaded in the two groups. 
Due to the fact that the cells were more likely to form single type spheroids (either MSC 
or islet-only spheroids), we completed additional analysis on the hybrids. As shown in Figure 
19C, the proportion of MSCs or islet cells in the hybrid spheroids (containing both cell types) 
followed the loading proportions. There were more islet cells and fewer MSCs in the group 














Figure 19. Co-localization of islet cells and MSCs.  
A) In order to track the co-localization of the groups of cells during reaggregation, MSCs were 
stained with CFDA-SE (green) and islet cells stained with DiI (red). Representative images of 
the resulting spheroids show the presence of the two different cell types when loaded with 
different proportions of islet cells. Scale bar = 100µm. B) The proportion of spheroids 
containing a mixture of both cell types was calculated according to the loading protocol (% of 
islet cells present at the time of spheroid formation). Even when different proportions of both 
cell types were loaded in the 50% and 75% islet cell group, there was no significant difference 
in the proportion of hybrids or single-cell type spheroids. C) The proportion of MSCs and islet 
cells in the hybrid spheroids followed the proportion of both cell types loaded (160-245 
spheroids were analyzed per group). * indicates p < 0.05 for islet cell spheroids (red bar) and 








The potential change in spheroid size over the 14 day culture was important to 
determine. Figure 20A shows a field of spheroids and the possible time-induced changes in 
spheroid diameter. The average diameter of the spheroids increased slightly over the 14 day 
period in all the groups (Figure 20A). A significant increase in the diameter of the 100% islet cell 
group was surprising and warranted further investigation, because islet cells do not proliferate. 
On day 1, the majority of spheroids in all the groups were between 50-100µm in diameter 
(Figure 20B). On day 14, the 100% islet cell group showed a decline in the number of small islet 
spheroids (under 100µm), but also showed an increase in the number of larger spheroids (over 
100µm diameter; Figure 20C). We hypothesized that an apparent increase in the mean 
diameter at day 14 was either the result of loss of small islet spheroids during subsequent 
media changes or due to fusion of spheroids as they were in culture. However, other spheroid 
groups also illustrated a decline in the number of small spheroids and an increase in the 
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Figure 20. Size distribution of spheroids. 
The average diameter of spheroids in each group at day 1 and 14 was below 80µm.  * 
indicates p < 0.05. B) Spheroids with 0%, 50%, 75% and 100% islet cells had the highest 
proportion of spheroids with diameters in the range of 50-100µm at day 1. C) At day 14, 0% 
and100% groups had lesser proportion of spheroids with smaller diameter (below 100µm) 
and higher proportion of spheroids with diameters of 100- 150µm with respect to day 1. 50% 
and 75% group also had lesser proportion of smaller diameter (below 50µm) and higher 
proportion of spheroids with diameters 50-100µm. 350-2000 spheroids were analyzed per 
group. 





The percentage of dead cells (apoptotic and necrotic) from 1 to 14 days in the different 
groups is summarized in Figure 21. Initially, each group had less than 10% dead cells. Of all the 
groups, the 75% group had the lowest proportion of dead cells at day 1, with significantly less 
necrotic cells in comparison to the 0% and 50% groups and significantly less apoptotic cells in 
comparison to the 0%, 50% and 100% islet cell groups. Interestingly, there was higher 
percentage of cell death through apoptosis at day 1 for the 0% and 100% groups compared to 
the 50% and 75% hybrid groups. Both the 75% and 100% groups had statistically significant 
increases in the percentage of apoptotic and necrotic cells at day 14 with respect to day 1, with 
the 100% islet cell group showing significantly higher percentages of both apoptotic and necrotic 
cells with respect to all other groups at day 14. In contrast, the 0% and 50% group had 
significant decline in the proportion of apoptotic cells at day 14 with respect to day 1. MSCs 
alone (0% group) had significantly less apoptotic cells at day 14 with respect to 50%, 75% and 
100% groups. Thus, viability was maintained over time when MSCs were incorporated into the 








Figure 21. Percentage of cell death (apoptotic and necrotic cells).  
Cell death by necrosis and apoptosis was calculated for each group on days 1 and 14. All 
the groups had low initial cell death. Cell death was split almost evenly by apoptosis and 
necrosis in the two hybrid spheroid groups. @ indicates that within group 0% and 100% 
groups had higher proportion of cell death through apoptosis at day 1 (p < 0.05).  # 
indicates that 75% group had significantly less apoptotic and necrotic cells than 0% and 
50% groups at day 1 (p < 0.05). The 75% group also had significantly less apoptotic cells 
than the 100% group on day 1. ## indicates that 100% islet cell group had the highest 
proportion apoptotic and necrotic cells with respect to the 0%, 50% and 75% groups at day 
14 (p < 0.05). Cell death was evenly split between apoptosis and necrosis in all the groups 
at day 14, except in the 0% islet cell group, which had fewer apoptotic cells (indicated by 
@@ with p < 0.05)). 30- 150 islets were analyzed per group. * indicates p< 0.05. 















Glucose Stimulated insulin secretion 
Insulin secretion in response to different glucose concentrations was normalized to the 
number of spheroids in the assay to assess function (Table 5). Although not significantly 
different, all three groups of spheroids containing islets cells showed a trend towards greater 
insulin release with increased glucose concentrations and in response to depolarization with 
high potassium levels (Table 5). However, at the low glucose concentrations (2.4 and 16.8mM) 
the 50% islet cell group secreted approximately 1/2 the amount of the 100% group. Insulin 
secretion/spheroid for the high glucose and depolarization conditions was 1/4 and 1/8 of the 
level secreted by the spheroids with 100% islet cells. Spheroid groups with lower numbers of 
islet cells could not be expected to secrete the same amount of insulin as spheroids with only 
islet cells. Thus, we normalized the insulin secretion to the number of islet cells loaded into the 
mold in each group. After normalization with the islet cells loaded, a trend towards increased 
release of insulin to the increasing glucose concentrations was seen again in the 100% islet cell 
group but not in the other groups (Table 5). In fact, in the 50% islet cells group insulin secretion 
values at 22.4mM and 22.4mM glucose with depolarization were 5 and 22 times less than the 
100% islet cell group, respectively. Whereas in 75% group, insulin secretion values at 22.4mM 
and 22.4mM with depolarization were approximately 1.5 and 5.5 times less than 100% islet cell 
group. Thus, normalization by islet cell number still showed a decrease in insulin secretion in all 
hybrid spheroids with mixed MSCs and islet cells. GSIS was also performed for MSCs 




























































































































































































































































































































































































































































































































































































































































































































































































































The glucose sensitivity was calculated, based on the stimulation index (SI). SI was 
defined as the ratio of insulin secretion/ islet cell at 22.4mM glucose to a 2.4mM glucose 
challenge. The SI of spheroids with 100% islet cells demonstrated a superior response to a high 
glucose with values reaching slightly above 4 on day 1 (Figure 22). In contrast, the 75% groups 
had significantly less SI than 100% islet cell group with value slightly above 1, indicating no 
glucose sensitivity. Although not statistically different than the 100% islet cell group, the 50% 
group was approximately 1.7, which was still at least 2 times less than the spheroids with 100% 
islet cells. In analyzing the 14 day data, there was a significant decline in the number of 
spheroids in the 100% group. Therefore, the 14 day data point for that group consisted of only 1 
of the 3 trials, because the others trials did not have enough spheroids left in the culture. SI at 








Figure 22. Glucose stimulation index (SI) of spheroids.  
SI was defined as the ratio of insulin secretion/ islet cell at 22.4mM glucose to a 
2.4mM glucose challenge. 100% islet cell group had a robust response to 
glucose on day 1 with value around 4 but glucose sensitivity was lost at day 14. 
SI of spheroids containing 75% islet cells at day 1 was significantly less than 
100% islet cell group.  The 100% islet cell group and both the hybrid spheroid 
groups also had poor glucose sensitivity at day 14.  (Day 1 data, n=3 trials with 6 






Previous studies have used a variety of techniques to co-culture islet cells either directly 
or indirectly with MSCs. Rather than indirect co-culture using a transwell system (Karaoz, Genc 
et al. 2010, Scuteri, Donzelli et al. 2014), or direct co-cultures (Jung, Kim et al. 2011, Rackham, 
Dhadda et al. 2013), the current study attempted to co-culture different proportions of islet cells 
and MSCs by incorporating them into the same spheroids. We found that islet cells preferred to 
reaggregate in spheroids with other islet cells rather than in mixed hybrid spheroids with MSCs. 
To the best of our knowledge, the only other study attempting to create hybrid spheroids also 
found that without manipulating the cellular interaction to improve cohesiveness between MSCs 
and islet cells, MSCs and islet cells preferred to reaggregate with their own cell type (Hoffecker 
and Iwata 2014). 
The results of our study suggested that it is possible to create highly viable hybrid 
spheroids consisting of MSCs and islet cells. Hybrid spheroids containing different proportion of 
MSCs and islet cells maintained high viability even after 14 days in culture. These results are in 
agreement with the previous studies, which have shown that islet co-culture with MSCs 
improves the islet cell viability and survival (Park, Kim et al. 2009, Park, Kim et al. 2010, Scuteri, 
Donzelli et al. 2014). Other studies have reported that the viability of islets in direct co-culture 
was higher than islets in indirect co-culture or islets alone. However, in the published direct co-
culture study, viability was approximately 60% at 2 weeks (Jung, Kim et al. 2011), whereas our 
spheroids were approximately 90% viable at 2 weeks. The improved long-term viability in our 
study may have been due to the intermingling between the MSCs and the islet cells, as that has 
been shown to improve function (Jung, Kim et al. 2011, Rackham, Dhadda et al. 2013). 
However, size may also explain the improved viability over other studies. The only other 
published study that created hybrid spheroids failed to report their size, and they utilized a gel 




hybrid spheroids in our study had diameters less than 100µm, hence our hybrid spheroids were 
under the size limitation shown to cause core cell death (Williams, Huang et al. 2010). 
Unfortunately, the hybrid spheroids tested in this study had a diminished insulin 
secretion in relationship to glucose concentrations, even when insulin secretion/islet cell was 
estimated (Table 5). Our GSIS results are in contrast to previous studies that support the 
concept that MSCs improve insulin secretion of islets (Park, Kim et al. 2010, Jung, Kim et al. 
2011). Namely, Park et al. showed that when islets were in indirect co-culture with MSCs, there 
was no significant increase in GSIS at 60mg/dl (3.3mM) glucose, but at 300mg/dl (16.7mM) 
glucose, islets with MSCs showed a modest (37.5%) increase in the insulin secretion compared 
to islets cultured alone (Park, Kim et al. 2010). In another study, islets co-cultured with MSCs 
indirectly, showed no significant increase in insulin secretion, whereas islets directly co-cultured 
with MSCs had approximately 69% increase in insulin secretion at 2 weeks (Jung, Kim et al. 
2011). Cell death was prevented when MSCs were co-cultured with islets previously exposed to 
Further, a few studies have found that co-culturing of MSCs along with islets previously exposed 
to either cytokines or streptozotocin prevented cell death in islets and also maintained their SI/ 
glucose secretion (Karaoz, Genc et al. 2010, Yeung, Seeberger et al. 2012). In contrast to these 
positive results, we and others report a lack of enhanced glucose sensitivity with co-cultured 
MSCs. In one study, islets and MSCs were incubated for 3 hours in suspension resulting in 
adherence of the MSCs to the exterior of the islets. In this condition, the SI of the islet-MSCs 
spheroids was not significantly different than islets alone (Duprez, Johansson et al. 2011). In 
another study, when human islets were coated with MSCs and endothelial cells, the insulin 
secretion of these spheroids was not different than the islets alone (Johansson, Rasmusson et 
al. 2008). Karaoz et al. found that when islets were indirectly co-cultured with MSCs for 14 days 
and challenged with low and high conditions, there was no significant difference in the amount 




cultures were first stressed by exposure to streptozotocin, their insulin secretion was similar to 
normal non-stressed islets and better than stressed pure islets (Karaoz, Genc et al. 2010). 
Finally, even when spheroids formed by manipulating the cellular interaction in order to improve 
cohesion between islet cells and MSCs were exposed to 0.1 g/dl (5.55mM), 0.3g/dl (16.65mM) 
and then again to 0.1g/dl (5.5mM) glucose concentrations, there was no significant difference in 
the amount of insulin secreted at different glucose concentrations with respect to the non-
manipulated islets, hence showing that co-culturing did not improve glucose sensitivity 
(Hoffecker and Iwata 2014). In contrast, intermingling the islet cells and MSCs actually resulted 
in a decline in insulin secretion per cell. 
A major difference in our approach compared to the previous co-culture publications lies 
in our method for incorporating the MSCs into the islet spheroids in a way that altered the 
normal islet-to-islet cell interaction. While such a configuration dramatically improved islet 
viability, it failed to improve insulin secretion. It is quite possible that the 3D cell-to-cell 
interaction in an islet cell spheroid is essential to normal glucose sensing and insulin secretion. 
This theory is supported by different studies emphasizing the importance of cell-to-cell 
interactions between β-cells for normal functioning of islets (Halban, Wollheim et al. 1982, 
Pipeleers, in't Veld et al. 1982, Hopcroft, Mason et al. 1985, Hauge-Evans, Squires et al. 1999). 
The results of this study provide strong evidence supporting the importance of cell-to-cell 
interactions in islets for glucose-sensitive insulin secretion. 
4.6. Conclusion 
The purpose of this study was to measure changes in the morphology, survival and 
function of hybrid spheroids comprised of islet cells and MSCs in different proportions with the 
goal of improving islet culture. We show that hybrid spheroids have improved survival but islet 




spheroids. Thus, co-culturing islets and MSCs without disruption of the islet architecture may be 





















5.1. Summary of findings 
Kanslets, created by reaggregating islet cells, have previously been shown to have 
higher viability and greater in vitro insulin secretion than native islets. Furthermore, they have 
been successfully used for maintaining blood glucose levels in diabetic rats after transplantation 
(Ramachandran, Williams et al. 2013). Previous data on drug testing has shown that Kanslets 
can be used as an alternative tissue for drug screening/testing (Ramachandran, Peng et al. 
2014). To advance research in the field of diabetes, in this research, I worked on (1) optimizing 
the cryopreservation procedure of pancreatic islets, (2) optimizing the drug screening/discovery 
process for diabetic drugs as well as (3) optimizing the islet culture conditions utilizing Kanslets. 
Conventionally, islets have been cryopreserved as intact native islets (Rajotte, Warnock 
et al. 1983, Lakey, Rajotte et al. 2001). Many single cell types have shown to be more tolerant 
to cryopreservation procedure than multicellular structures like pancreatic islets. Accordingly, I 
proposed that pancreatic islets be cryopreserved as single cells and reaggregated in the 
micromold following thawing to form cryopreserved Kanslets. Cryopreserved Kanslets were 
highly viable and metabolically active. Cryopreserved Kanslets were able to restore and 
maintain blood glucose levels in diabetic rats until sacrificed at 10 months post transplantation. 
This technological advancement opens opportunities for building cell banks of islet cells with 
subsequent reaggregation into viable islets when needed for either islet transplantation or 
research. 
With cryopreservation techniques optimized, new applications for islets in research could 
be introduced. Bringing a new drug to the market is a lengthy and an expensive procedure. 
Much of the failure lies in the inability to reproduce the results in preclinical studies and in 
clinical trials. In addition, the number of repetitions at each stage of the drug screening 
discovery process creates added cost to the procedure. Hence, I proposed to create multi-donor 




method would provide an average drug response potentially eliminating the need for assay 
repetition. Thawing and mixing cells from two cryopreserved donors generated highly viable 
Kanslets, but neither the multi-donor nor did the single-donor Kanslets used in the experiments 
were highly responsive to the drugs tested. 
We also combined different cell types into the micromold to create hybrid Kanslets. 
Specifically, we co-seeded mesenchymal stem cells (MSCs) along with islet cells in the 
micromold, as MSCs have recently been of interest for their potential benefits to islet viability 
and function. Culturing islets in direct contact with MSCs has been shown to be superior to 
indirect co-culture where islets and MSCs are separated by inserts. In order to have MSCs in 
even more proximity to islet cells, I proposed to integrate MSCs with islets cells during 
reaggregation to create hybrid spheroids of MSCs and islet cells. I bioengineered hybrid 
spheroids containing different proportion of MSCs and islet cells, and performed in vitro studies 
to look at their architecture, diameter and stimulation index. Hybrid spheroids were viable 
irrespective of the proportion of MSCs incorporated. However, functionally hybrid spheroids 
were not sensitive to the increasing glucose challenges when compared to spheroids containing 
100% islet cells, providing the evidence that the cellular interaction between β-cells is important 






5.2.1. The implications for islet transplantation  
Cryopreservation of pancreatic islets is necessary to make islet transplantation a 
feasible option for more people with diabetes. Long-term storage provides enough time for 
organization of islet transplantation, for tissue matching, and to accumulate the minimum 
number of islets from multiple donors, needed for a successful transplant. Thus, the findings in 
this dissertation may have direct and significant implications to the world of islet transplantation. 
Islet transplantation is the isolation of pancreatic islets from a donor, and placement into 
either the recipient’s hepatic portal system or under the kidney capsule or omentum. Since the 
initial attempts in 1882, the field of islet transplantation has evolved significantly. With the 
advent of the Edmonton protocol in 2000 through 2012, more than 750 islet transplantations had 
been performed worldwide (McCall and Shapiro 2012). It has been reported multiple times that 
the number of islets transplanted is one of the most important factors in determining the success 
of the transplantation (Shapiro, Lakey et al. 2000, Clayton, Davies et al. 2003, Morgan, 
Theruvath et al. 2012). For a successful transplantation, it is recommended to that at least 
9000IEQ/kg of body weight of the recipient be transplanted, and this often requires islets from 2-
4 donors (Markmann, Deng et al. 2003). However, because of the limited availability of donors 
at any given time, typically the recipient must undergo repeated transplant procedures to 
eventually get to the minimum necessary islet volume. 
In the clinic, islet transplantation is performed immediately after isolation of the 
pancreatic islets from the donor. If the islets do not qualify for islet transplantation or if a 
sufficient amount of islets cannot be obtained from the isolation, then islets are shipped for 




procedure of pancreatic islets so that islets can be pooled from different donors and it would 
also allow clinicians more flexibility in scheduling the islet transplantation. 
In addition to the shortage of islets from donors and the inability to pool them into one 
transplant procedure, another important confounding factor in islet transplantation is the loss of 
functional islets during the early post transplantation period. This loss of function has 
detrimental effects on the outcome of individual grafts (Davalli, Scaglia et al. 1996). Previous 
studies have shown that a decline in islet function and survival is highest within the first week 
after islet transplantation (Davalli, Ogawa et al. 1995, Jirak, Kriz et al. 2009). Inadequate blood 
supply is considered as one of the reasons for immediate islet loss and graft failure. Newly 
transplanted islets experience limited blood supply for several days before the blood vessels 
start to form. Even when the new blood vessels have formed, islets still receive a diminished 
nutrient supply compared to islets in the native pancreas. Notably, small diameter islets have 
shorter diffusion distance than large diameter islets. Indeed, small islets have shown to be more 
viable in culture and more successful in islet transplantation. Our micromold restricts the size of 
the Kanslets to 125-150µm in diameter and Kanslets created by reaggregating islet cells in 
micromold have shown to be highly viable and were also successful in reversing hyperglycemia 
in diabetic rats (Ramachandran, Williams et al. 2013). Cryopreserved Kanslets were created by 
reaggregating cryopreserved and thawed single islet cells in the micromold. Cryopreserved 
Kanslets were highly viable and reversed hyperglycemia in diabetic rats even when 15%-30% 
less islet volume was transplanted with respect to fresh native islets. Multiple previous studies 
reported that cryopreservation improves the purity of islets. Although we did not assess the 
purity of islets after cryopreservation in our study, but one of the factors affecting our success 
could be the improved purity of the CP Kanslets. The efficiency of small CP Kanslets with their 




One of the major limitations of islet transplantation is the limited availability of pancreatic 
tissue, which does not proliferate in culture. Researchers are currently looking at different 
sources like bone marrow stem cells, hepatocytes or intestine epithelial cells, pancreatic acinar 
or ductal cells to generate pancreatic islets (Todorov, Omori et al. 2006). Alternatively, 
strategies for expanding human islets in culture are also being investigated (Kayali, Flores et al. 
2007). Some of these studies have shown promising results in expanding and then 
differentiating ductal cells into islet like tissue (Bonner-Weir, Taneja et al. 2000). Our novel and 
successful cryopreservation technique, enables long term storage of expanded or differentiated 
cells, which can subsequently be thawed and reaggregated into Kanslets using our micromold 
whenever needed for islet transplantation. 
In the study described in the 4th Chapter, I integrated MSCs with islet cells into 
spheroids. These hybrid spheroids were highly viable in long term culture. However, the hybrid 
spheroids could not maintain in vitro function of insulin secretion. In vivo studies might provide 
more insight into possible overall effects of the integrating of MSCs and islet cells.  As I showed 
with the cryopreservation study, there was a less than impressive in vitro response to glucose. 
Yet, the CP Kanslets impressively reversed diabetes in rats for 10 months. As MSCs are 
integrated with islet cells in spheroids, these hybrid spheroids have continuous exposure to the 
benefits of MSCs. It would be important in future studies to see if hybrid spheroids would 
provide better transplantation outcomes than islets alone, and if they could help with islet 
engraftment, circumventing the need for islet re-transplantation. 
5.2.2. The implications for drug testing and diabetes research 
The ability to bank human islet cells, and subsequently reaggregate them into viable 
islets, opens new opportunities for the utilization of human islets, for drug screening and 
therapeutics. Utilizing the approach of dispersing native islets and allowing them to reaggregate, 




significant increase in the number of people suffering from type 2 diabetes, there is definitely a 
need to discover new anti-diabetic drugs. Traditionally, 2 dimensional (2D) cell cultures have 
been used to perform drug testing for anti-diabetic drugs. In 2D cell cultures, cells are cultured 
on flat, rigid plastic substrates, which are very different from cell’s in vivo architecture. 
Bioengineered Kanslets created using our micromold are 3D structures that offer a practical 
alternative to 2D cell culture. Kanslets have been tested previously for different diabetic drugs, 
and the results have been compared with native human islets, and rat islets. Kanslets were 
responsive to different drugs, and in some cases, were an even better predictor of a drug 
response (Ramachandran, Peng et al. 2014). According to the Tufts Center for the Study of 
Drug Development, currently it takes more than 10 years, and approximately 2.6 billion dollars 
from drug discovery stage to get that drug to the market (Avorn 2015). 
During the preclinical phase when in vitro drug studies are conducted, the assays 
typically need to be repeated to estimate an average response, whether it is for testing efficacy 
or toxicity. In this project, I desired to determine whether it was possible to combine the islet 
cells of two different donors, and form multi-donor Kanslets, and determine whether these multi-
donor Kanslets could give an average dose response compared to the two individual donors 
used in the study. Unfortunately, our single- and multi-donor Kanslets were not as responsive to 
the different drugs tested as was expected. 
It took several months to collect islets from 4 different donors, and because of that slow 
retrieval process, islet cells had to be cryopreserved for 5-7 months. I believe that the longer 
duration of cryopreservation could have affected the results of our drug studies. However, 
without repeating the same drug studies with Kanslets formed from cells cryopreserved for only 
a short length of time, this hypothesis can’t be confirmed at this time. The multi-donor concept 




efficient. However, it is possible that this concept works only with fresh Kanslets instead of 
cryopreserved ones. 
While testing fresh Kanslets is sound theoretically, the implementation of such a plan 
would be very difficult. There is always a gap of days or months between the availability of islets 
from different donors through national consortium that supplies the tissue for research. Working 
with fresh islets to create multi-donor Kanslets would require the arrival of a minimum of two 
donors meeting the inclusion criteria within a 3 day period. That would only be possible, if the 
source of tissue was a company like Prodo Laboratories (Irvine, CA). However, their charges for 
islets are nearly 4 times higher than those of the non-profit national consortium. This same 
problem would prevent researchers from simply mixing intact native islets from different donors 
for a drug screen. In addition, using mixed intact native islets adds the complication of varying 
islet sizes that require an additional, and often ineffective step, of normalizing all results to islet 
volume or cell number (Ramachandran, Huang et al. 2015). 
In our drug testing experiments, we tested glibenclamide, an insulin secretagogue, and 
somatostatin, an insulin secretion inhibitor, which act through potassium and calcium channels, 
respectively. In my 3rd Chapter, I did not look at the integrity of these channels after 
cryopreservation and thawing. It is possible that the process of cryopreservation left the cells 
viable, but damaged the individual channels, however until and unless further analysis is 
completed on the integrity and function of channels, we cannot conclude anything. It would be 
an interesting, and useful future study to investigate the functioning of channels after 
cryopreservation and thawing. 
As an alternative to the CP islet clusters, there are multiple β-cell lines that have been 
discovered and used for drug testing. Although it is known that the β-cell lines do not fully mimic 
the in vivo insulin secretory response to glucose, they can still serve as an early (1st stage) 




transgenic C57BL/6 mouse insulinoma cell line (MIN6) and insulinoma cell line (INS-1) retain 
normal glucose regulation of insulin release (Miyazaki, Araki et al. 1990, Efrat 1999). Our own 
laboratory has a manuscript in press using a humanized version of INS-1 in 3D culture to test 
known diabetes drugs (Amin, Ramachandran et al, 2016). Other than our own laboratory work, 
other groups have used these cell lines to create 3D clusters by allowing cells to reaggregate in 
medium droplets using either low attachment plates or agarose gels. With these techniques, the 
diameters of the final clusters are quite variable and tend to be larger than the Kanslets tested 
here (Longati, Jia et al. 2013, Wen, Liao et al. 2013). 3D clusters of β-cell lines made using our 
micromold can be an alternative way to perform drug testing. 
Another challenge for drug testing using human islets has been the length of the study. 
Many drugs are not designed to induce the release of insulin upon ingestion. Rather, the target 
of the drug is designed to enhance islet function over a long period of time. Thus, exposing 
islets or Kanslets to a single application of the drug and examining immediate effects may result 
in false negative findings. Yet, functional islets cannot be cultured for the amount of time 
necessary to uncover long-term effects. Maintaining the viability and function of islets during 
extended culture has been a challenge that researchers have attempted to overcome. Co-
culturing islet cells with MSCs, either by separating both cell types using inserts, or by allowing 
both cell types to be in contact with each other, is one way to attempt to extend the life of the 
islet cells (Park, Kim et al. 2010, Jung, Kim et al. 2011). I integrated MSCs along with islet cells 
in different proportions into spheroids so that MSCs are in close proximity to islet cells. Hybrid 
spheroids had excellent viability but, surprisingly, could not maintain their in vitro function. We 
hypothesize that the loss of the endocrine cell-to-cell contact may have been the cause of the 
decreased function. The findings emphasize the importance of the interaction among the natural 




functional islet studies, but would not be appropriate as a therapeutic agent, such as for 
transplantation. 
MSCs obtained from other sources like placenta or umbilical cord have higher 
proliferative and differentiation capabilities than MSCs derived from adult tissues like bone 
marrow (Hass, Kasper et al. 2011). One of the possible ways that could have helped the hybrid 
spheroids secrete more insulin would have been if the bone marrow MSCs in our study had 
differentiated into β-cells. Due to difficulties faced with staining MSCs, I could not determine 
whether MSCs differentiated into β-cells or any other endocrine cell type. The challenge came 
because the antibodies normally used to identify MSC’s, also co-stained the islet cells. When 
hybrid clusters were stained for MSCs, β-cells and α-cells, MSCs co-stained with α-cells (Figure 
23). In order to confirm if MSCs are differentiating into α-cells, we stained MSCs grown on 
microscope slides for insulin (β-cells), glucagon (α-cells) and somatostatin (δ-cells), MSCs 






Figure 23. Immunofluorescence image of hybrid 
clusters. 
Hybrid clusters containing islet cells and MSCs were stained 
for β-cells (A, green), α-cells (B, blue), MSCs (C, red) and β-, 
α-, MSC cells (D). 
 
Figure 24. Immunofluorescence image of MSCs.  





5.3. Future directions 
Although not ideal, when research is initiated in an area where little previous data exists, 
extrapolation from work in related areas may be necessary. The present study is one of the only 
studies which attempted to examine how the property of reaggregation of islet cells can be used 
to advance different fields of diabetes research such as cryopreservation of pancreatic islets, 
drug screening discovery for diabetic drugs and pancreatic islet health. 
5.3.1. Refinement of steps in our cryopreservation protocol 
We looked at how islet cells could be reaggregated to form highly viable and functional 
islets after cryopreservation. However we had approximately 21% islet cell loss during 
cryopreservation and thawing even under our optimized conditions. Although this loss is 
comparable to previous cryopreservation procedures, it still would be wise to work on the 
refinement of the steps in the single cell cryopreservation protocol so as to have even less 
tissue loss. Possible ways through which this could be achieved could be by making some 
modifications in our single cell cryopreservation protocol, like trying to minimize the steps 
involved in the cryopreservation process. It would be interesting to test whether a controlled rate 
of cooling using a controlled rate freezer could help to achieve even better outcomes than 
cooling using a Coolcell. 
5.3.2. Determining the appropriate length of time for cryopreservation of islet cells  
Our studies were the first to suggest that the duration of cryopreservation has a strong 
influence on islet function for both intact islets and single islet cells. In Chapter 2, when native 
islets were cryopreserved for 4 weeks or longer their viability was reduced by approximately 
80%, whereas islets cryopreserved as single cells were highly viable when cryopreserved for up 
to 4 months. However, in work described in Chapter 3, when we cryopreserved islet cells for 5-7 




responsive to increasing glucose concentrations, suggesting that there may be a cut off time 
point for cryopreservation when the cells may still be alive, but not functional. In future studies, it 
will be imperative to determine the maximal time that cells can be cryopreserved without losing 
their function. This will add to data currently obtained in this dissertation, and in the future, will 
help clinicians and researchers determine how long islet cells can be cryopreserved, so that 
viable and functional tissue could be obtained after thawing. 
5.3.3. Damage to potassium or calcium channels during cryopreservation and thawing 
Our single-donor and multi-donor Kanslets, although being highly viable, did not respond 
to different drugs tested. Potassium and calcium channels play an important part in regulating 
insulin secretion upon glucose stimulation. One of the other possible reasons for islets not 
responding to different drugs being tested could be damage to the ion channels of β-cells. 
Electrophysiological studies, such as patch clamp, could help determine whether the 
cryopreservation procedure damages the ion channels. 
5.3.4. Multi-donor drug testing with CP Kanslets (cryopreserved for short length of 
time), fresh Kanslets and native islets  
Our cryopreserved single-donor/multi-donor Kanslets were not responsive to different 
drugs tested. Although not tested, but we assume that longer duration of cryopreservation of our 
single cells could have affected the results of drug testing experiments; repeating this 
experiment using Kanslets cryopreserved for shorter duration would be important. In the future, 
it would be worthwhile to experiment using fresh islet cells, and if at all possible, to get the islets 
from different donors at the same time. If the multi-donor concept does not work with fresh 
Kanslets also, I think performing multi-donor drug testing by simply mixing intact native islets 





5.3.5. Integrating lower proportions of MSCs into spheroids 
Irrespective of the proportion of MSCs and islet cells in the spheroids, all spheroids 
groups had excellent viability even long term in culture. A major difference in our approach was 
the incorporation of the MSCs into the islet clusters in a way that disturbed the normal islet-to-
islet cell interaction.  While such a configuration dramatically improved islet viability, it failed to 
improve insulin secretion.  It is quite likely that the 3D cell-to-cell interaction in an islet cell 
cluster is essential to normal glucose sensing and insulin secretion. In future studies, it would be 
interesting to determine if lower proportions of MSCs (i.e well below 25%) incorporated into the 
islet spheroids would maintain or improve insulin secretion in long term culture.  
5.3.6. Analysis of immune modulatory, angiogenic, anti-apoptotic and trophic factor 
effects of hybrid spheroids  
When we created these hybrid spheroids of MSCs and islet cells, we completed in vitro 
analysis of their diameter, viability as well as insulin secretion. Performing additional 
experiments on the culture supernatant to identify if hybrid clusters released trophic molecules 
like interleukin (IL)-6, vascular endothelial growth factor (VEGF), hepatocyte growth factor 
(HGF), transforming growth factor- β (TGF- β) and tumor necrosis factor α-(TNF α), would have 
provided us more information on the function of the MSCs. Looking at the expression of various 
molecules like Ki67 and anti- apoptotic molecules like heat shock protein would have helped us 
provide more information about the behavior of MSCs when they are contained in a defined 
geometry of a hybrid cluster. 
5.3.7. Performing transplantation studies with hybrid clusters 
Our data suggested that hybrid spheroids produced with 50% MSCs and 50% islet cells 
had a stimulation index not statistically significantly different from spheroids containing 100% 




could restore normal blood glucose levels after transplantation in diabetic rodent models. Also, it 
would be interesting to elucidate the potential benefits of islet-MSC hybrid spheroids for grafts 
survival and function. Future research could examine possible mechanisms for graft survival, 
which may include prevention of islet loss during the early days of transplantation, prevention of 
immune rejection, or promotion of neovascularization. 
5.4. Overall summary 
This dissertation looked at the implications of islet cells reaggregation to different areas 
like cryopreservation, drug testing and islet health in culture. This project is innovative because 
this is the first study to cryopreserve human islets as single cells and later reaggregate them to 
form viable islets. The work resulted in a US patent-pending. Results of this study will help 
optimize islet storage techniques. The ability to bank the human islets cells will open up new 
opportunities for utilization of human islets for diabetes research and islet transplantation. This 
is also the first study to create multi-donor islet clusters containing islet cells from two different 
human donors for drug testing procedures. Furthermore, to the best of my knowledge, this is the 
first study to successfully create hybrid spheroids containing islet cells and MSCs without any 
chemical manipulation of any of the two cell types. With this dissertation, we have obtained a 
greater understanding of implications of islet cell reaggregation to advance the field of diabetes 
research. The results of this study will have a significant positive impact on the current islet 
transplantation research. I also expect that all the work in this dissertation will not only unfold 
the complexities concerning drug testing and islet culturing, but will also be a helpful guide to 
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